<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Dysmenorrhea in adult females: Treatment</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Dysmenorrhea in adult females: Treatment</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Dysmenorrhea in adult females: Treatment</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Roger P Smith, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Andrew M Kaunitz, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Robert L Barbieri, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Kristen Eckler, MD, FACOG</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Sep 14, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Primary dysmenorrhea refers to the presence of recurrent, crampy, lower abdominal pain occurring during menses and the absence of demonstrable disease. Secondary dysmenorrhea is the occurrence of the same symptoms in response to clinically identifiable or suspected underlying pathology, such as endometriosis or adenomyosis. Treatment approaches must address the pain and, for secondary dysmenorrhea, the underlying etiology. </p><p>The management of patients with dysmenorrhea will be reviewed here. The pathogenesis, clinical manifestations, and diagnosis of primary dysmenorrhea and dysmenorrhea in adolescents are discussed separately. </p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/5483.html" rel="external">"Dysmenorrhea in adult females: Clinical features and diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/5847.html" rel="external">"Primary dysmenorrhea in adolescents"</a>.)</p><p></p><p>In this topic, when discussing study results, we will use the terms "woman/en" or "patient(s)" as they are used in the studies presented. However, we encourage the reader to consider the specific counseling and treatment needs of transmasculine and gender-expansive individuals.</p><p class="headingAnchor" id="H4034355612"><span class="h1">TERMINOLOGY</span><span class="headingEndMark"> — </span>For clinical purposes, dysmenorrhea is divided into two broad categories, primary and secondary:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Primary dysmenorrhea</strong> refers to the presence of recurrent, crampy, lower abdominal pain that occurs during menses in the absence of demonstrable disease that could account for these symptoms. The diagnosis of primary dysmenorrhea, which is one of exclusion, is made more often in adolescents and young adult females. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Secondary dysmenorrhea</strong> has the same pain symptoms but occurs in individuals with a disorder that could account for their symptoms, such as endometriosis, adenomyosis, or uterine fibroids. Patients with these diseases often have clinical features that separate them from primary dysmenorrhea, including a large uterus, pain with intercourse, and resistance to effective treatments. </p><p></p><p class="headingAnchor" id="H28816178"><span class="h1">OUR APPROACH</span><span class="headingEndMark"> — </span>The goal of treatment is to provide adequate relief of pain. At a minimum, pain relief should be sufficient to allow patients to perform most, if not all, of their usual activities and to reduce the productivity loss commonly associated with dysmenorrhea [<a href="#rid1">1</a>]. Treatment of primary dysmenorrhea can be initiated empirically  (<a class="graphic graphic_algorithm graphicRef126057" href="/d/graphic/126057.html" rel="external">algorithm 1</a>). Laboratory tests, imaging studies, and/or laparoscopy are not required to definitively exclude causes of secondary dysmenorrhea when a detailed history and physical examination strongly support the diagnosis, particularly in adolescents. Relief of symptoms with standard treatments, as reviewed below, further supports the diagnosis of primary dysmenorrhea. If symptoms do not sufficiently respond to standard treatments, we begin an evaluation for causes of secondary dysmenorrhea. (See  <a class="medical medical_review" href="/d/html/5483.html" rel="external">"Dysmenorrhea in adult females: Clinical features and diagnosis", section on 'Diagnostic evaluation'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Baseline interventions</strong> – General measures for management include patient education and reassurance. Treatment is supportive and should be guided by individual needs, as the severity of pain and degree of limitation of activity vary widely among individuals with dysmenorrhea. Symptom grading systems exist but are often limited to research settings  (<a class="graphic graphic_table graphicRef65347" href="/d/graphic/65347.html" rel="external">table 1</a>). The initial approach includes a discussion of nonpharmacologic interventions that can be helpful, such as exercise and application of a heat pack to the lower abdomen  (<a class="graphic graphic_algorithm graphicRef126057" href="/d/graphic/126057.html" rel="external">algorithm 1</a>). (See <a class="local">'Baseline interventions'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>First-tier treatment </strong>– For individuals who do not have adequate relief with baseline interventions or who desire immediate pharmacologic therapy, first-line treatment options include nonsteroidal anti-inflammatory drugs (NSAIDs), <a class="drug drug_general" data-topicid="9242" href="/d/drug information/9242.html" rel="external">acetaminophen</a> (paracetamol), and/or hormonal contraception  (<a class="graphic graphic_algorithm graphicRef126057" href="/d/graphic/126057.html" rel="external">algorithm 1</a>). Hormonal contraception includes combined estrogen-progestin products (oral pills, transdermal patches, and vaginal rings) and progestin-only options (implant, injection, intrauterine device, and oral pills). Choice of treatment order depends on the clinical needs and preferences of the patient. For those with primary dysmenorrhea desiring contraception, hormonal contraception is a logical initial choice. Initiating hormonal contraception may also be appropriate for persons who do not need contraception (eg, they are not sexually active with a male partner) and do not currently wish to conceive. For individuals who prefer not to use hormonal treatment, NSAIDs or acetaminophen are a logical first choice. Treatment typically begins just prior to or with the onset of menses and continues for two to three days. Treatment duration depends on the duration of the patient's menses and symptom pattern. Some patients may benefit from combinations of treatments. Patient-specific factors, such as personal treatment goals and the cost and convenience of various treatments, help guide treatment selection. (See <a class="local">'First-tier'</a> below.) </p><p></p><p class="bulletIndent1">We begin the initial treatment for two to three months and then reassess the patient's symptoms. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients whose symptoms improve somewhat but still have pain, we discuss adding an additional treatment from the first-tier category and continuing the initial treatment (ie, combination treatment). As an example, for a patient whose symptoms improve with NSAID therapy but not enough to resume the usual range of activities, we offer additional treatment with a hormonal contraceptive. Treatment with both hormonal contraception and NSAIDs may be effective in those who remain symptomatic on either therapy alone.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients with no or minimal response to treatment after two or three months, we offer a treatment change to the other first-tier options and stop the initial intervention. In addition, reevaluation of the original diagnosis is always indicated when therapies do not result in the anticipated level of response. </p><p></p><p class="bulletIndent1">We observe patients on combination therapy or treatment change for up to an additional three months. Patients who have adequate symptom response continue on the effective therapy. Patients who do not have an adequate response are then reevaluated for underlying causes of their dysmenorrhea (ie, secondary dysmenorrhea). </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Reevaluate for underlying causes of dysmenorrhea</strong> – Patients who do not achieve adequate pain relief after three to six months of treatment with NSAIDs and/or hormonal contraceptives, either alone or in combination, may have secondary dysmenorrhea (ie, dysmenorrhea related to underlying pathology)  (<a class="graphic graphic_table graphicRef78903" href="/d/graphic/78903.html" rel="external">table 2</a>). Clinical features suggesting secondary dysmenorrhea include persistent symptoms resistant to standard treatment, missing work or school, and multiple visits to the emergency department or urgent care clinics for pain with menses. We repeat a targeted diagnostic evaluation that is guided by the unique history and symptoms of each patient. We particularly focus our evaluation on common causes of secondary dysmenorrhea, including endometriosis and adenomyosis.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>(See  <a class="medical medical_review" href="/d/html/5483.html" rel="external">"Dysmenorrhea in adult females: Clinical features and diagnosis", section on 'Diagnostic evaluation'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>(See  <a class="medical medical_review" href="/d/html/7384.html" rel="external">"Endometriosis in adults: Pathogenesis, epidemiology, and clinical impact"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>(See  <a class="medical medical_review" href="/d/html/5489.html" rel="external">"Uterine adenomyosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Second-tier treatment</strong> – For patients with continued menstrual pain despite the above treatments, we next offer a trial of transcutaneous electrical nerve stimulation and/or empiric treatment with gonadotropin-releasing hormone analogs, including agonists (eg, <a class="drug drug_general" data-topicid="9549" href="/d/drug information/9549.html" rel="external">leuprolide</a> acetate, <a class="drug drug_general" data-topicid="9673" href="/d/drug information/9673.html" rel="external">nafarelin</a>, <a class="drug drug_general" data-topicid="8500" href="/d/drug information/8500.html" rel="external">goserelin</a>) and antagonists (eg, <a class="drug drug_general" data-topicid="118522" href="/d/drug information/118522.html" rel="external">elagolix</a>). These medications have proven efficacy for treatment of endometriosis-related dysmenorrhea. Their role in patients without endometriosis is not known. However, the time required for treatment, side effects, and cost may limit use of these therapeutic options. Patients who decline these treatments or who do not improve then generally proceed with laparoscopy. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>(See <a class="local">'Transcutaneous electrical nerve stimulation'</a> below.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>(See <a class="local">'Empiric GnRH analog therapy'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Role of laparoscopy</strong> – Patients who do not respond to the above interventions have a high likelihood of pelvic pathology. For this reason, we offer diagnostic laparoscopy for individuals with dysmenorrhea who have not had adequate relief after three to six months of NSAIDs and/or hormonal contraception. The most common diagnosis is endometriosis. (See <a class="local">'Role of laparoscopy'</a> below.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Refractory dysmenorrhea</strong> – Despite the above treatments, a minority of patients will continue to have dysmenorrhea that limits their function. For patients whose dysmenorrhea appears to be related to heavy menstrual bleeding and who do not desire future childbearing, endometrial ablation is an option. For patients who have exhausted all treatment options and have completed their childbearing, hysterectomy is the definitive treatment. We do not advise nerve transection procedures for treatment of dysmenorrhea, although there may be a role in select patients with chronic midline pelvic pain. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>(See <a class="local">'Surgery for refractory dysmenorrhea'</a> below.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>(See <a class="local">'Ineffective or unproven treatments'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Inclusion of supportive therapies</strong> – Supportive therapies, such as behavioral counseling, complementary or alternative medicine, or dietary changes, can be started at any time by interested patients and used in conjunction with the treatments above. While the available supporting data are weak, the risks appear to be low. (See <a class="local">'Supportive therapies'</a> below.)</p><p></p><p class="headingAnchor" id="H3"><span class="h1">BASELINE INTERVENTIONS</span><span class="headingEndMark"> — </span>We begin with a discussion of self-care approaches to pain relief, especially for those who want to avoid drug therapy. We discuss the approaches in the order below.</p><p class="headingAnchor" id="H964541073"><span class="h2">Exercise</span><span class="headingEndMark"> — </span>The body of evidence supports a role for exercise in the treatment of dysmenorrhea. However, the optimal type, duration, and frequency of exercise to relieve symptoms is not known. A meta-analysis of 11 trials reported reduced pain intensity and duration for exercise versus any nonexercise comparator, although result heterogeneity was high [<a href="#rid2">2</a>]. Subsequent small trials have also reported reduced pain intensity and duration with exercise compared with usual care [<a href="#rid3">3-8</a>]. One pilot study reported exercise-mediated increases in progesterone and reductions in pain mediators as potential mechanisms for the response [<a href="#rid9">9</a>]. As there are multiple health benefits to exercise and the risk of harm is low, increasing physical activity is a reasonable approach to reduce dysmenorrhea. (See  <a class="medical medical_review" href="/d/html/2786.html" rel="external">"The benefits and risks of aerobic exercise"</a>.)</p><p class="headingAnchor" id="H4"><span class="h2">Heat</span><span class="headingEndMark"> — </span>In randomized trials, application of heat to the lower abdomen was effective for relief of dysmenorrhea [<a href="#rid10">10,11</a>]. Heat had similar efficacy as <a class="drug drug_general" data-topicid="8547" href="/d/drug information/8547.html" rel="external">ibuprofen</a> [<a href="#rid10">10,12</a>] and was more effective than <a class="drug drug_general" data-topicid="9242" href="/d/drug information/9242.html" rel="external">acetaminophen</a> [<a href="#rid11">11</a>]. Most individuals find applying heat more cumbersome than taking oral medications, but it has no side effects. Heat therapy may improve the efficacy of other treatments [<a href="#rid13">13</a>].</p><p class="headingAnchor" id="H8"><span class="h1">FIRST-TIER</span><span class="headingEndMark"> — </span>Nonsteroidal anti-inflammatory drugs (NSAIDs), <a class="drug drug_general" data-topicid="9242" href="/d/drug information/9242.html" rel="external">acetaminophen</a> (paracetamol), and hormonal contraceptives are the mainstays of drug therapy. No randomized trials have compared the efficacy of NSAIDs versus hormonal contraception for treatment of primary dysmenorrhea. If treatment with one of these agents fails after two or three months, we advise a course of treatment with the other. Treatment with both hormonal contraception and NSAIDs may be effective in those who remain symptomatic on either drug alone. In addition, reevaluation of the original diagnosis is always indicated when therapies do not result in the anticipated level of response. (See <a class="local">'Our approach'</a> above.)</p><p class="headingAnchor" id="H1582715723"><span class="h2">Nonhormonal therapy</span><span class="headingEndMark"> — </span>For patients who do not desire hormonal contraception or prefer/need to avoid hormonal therapy, we suggest treatment with NSAIDs. <a class="drug drug_general" data-topicid="9242" href="/d/drug information/9242.html" rel="external">Acetaminophen</a> is an alternative treatment for patients who cannot tolerate NSAIDs.</p><p class="headingAnchor" id="H9"><span class="h3">Nonsteroidal anti-inflammatory drugs</span><span class="headingEndMark"> — </span>NSAIDs more effectively treat dysmenorrhea-related pain compared with placebo. A meta-analysis including 80 trials reported that NSAIDs were more effective than placebo for patients with primary dysmenorrhea (odds ratio [OR] 4.37, 95% CI 3.76-5.09, 35 trials for comparison) [<a href="#rid14">14</a>]. However, NSAIDs were also associated with a 30 percent increased likelihood of adverse effects overall (OR 1.29, 95% CI 1.11-1.51, 25 trials) and a nearly 60 percent increased risk of gastrointestinal side effects (OR 1.58, 95% CI 1.12-2.23, 14 trials). Most of the adverse effects were mild.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Choice of agent</strong> – Although the above meta-analysis and other studies did not report efficacy differences across nonspecific NSAIDs [<a href="#rid14">14-17</a>], others suggest that differences exist and that fenamates (<a class="drug drug_general" data-topicid="9601" href="/d/drug information/9601.html" rel="external">mefenamic acid</a>, tolfenamic acid, flufenamic acid, <a class="drug drug_general" data-topicid="9599" href="/d/drug information/9599.html" rel="external">meclofenamate</a>, <a class="drug drug_general" data-topicid="8668" href="/d/drug information/8668.html" rel="external">bromfenac</a>) may have slightly better efficacy than the phenylpropionic acid derivatives (<a class="drug drug_general" data-topicid="8547" href="/d/drug information/8547.html" rel="external">ibuprofen</a>, <a class="drug drug_general" data-topicid="9682" href="/d/drug information/9682.html" rel="external">naproxen</a>) [<a href="#rid18">18,19</a>]. Both fenamates and phenylpropionic acid derivatives inhibit prostaglandin synthesis, but fenamates also block prostaglandin action, which may account for their enhanced effectiveness in some studies. At least one network meta-analysis has reported that fenamates and phenylpropionic acid derivatives provided better pain relief compared with <a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">aspirin</a> [<a href="#rid20">20</a>]. (See  <a class="medical medical_review" href="/d/html/7989.html" rel="external">"NSAIDs (including aspirin): Pharmacology and mechanism of action"</a>.)</p><p></p><p class="bulletIndent1">As there are insufficient data on which to base a recommendation for one class of agents or the other, we take the following approach to NSAID treatment, although other treatment regimens are reasonable:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>We begin treatment with a phenylpropionic acid derivative prescribed at the upper end of the dose range  (<a class="graphic graphic_table graphicRef71912" href="/d/graphic/71912.html" rel="external">table 3</a>). These drugs are relatively inexpensive, available without prescription, easy to dose, and of demonstrated efficacy. We prescribe <a class="drug drug_general" data-topicid="8547" href="/d/drug information/8547.html" rel="external">ibuprofen</a> 400 to 600 mg every four to six hours or 800 mg every eight hours to a maximum dose of 2400 mg per day, starting with the onset of symptoms or menses, and continue this dose for two or three days based on the patient's usual symptom pattern. In the above meta-analysis [<a href="#rid14">14</a>], some of the included studies did not indicate when participants initiated NSAIDs, others stated "at onset of pain," while others specified "at onset of symptoms." The US Food and Drug Administration packaging insert for ibuprofen indicates the drug should be started "for the treatment of dysmenorrhea, beginning with the earliest onset of such pain" [<a href="#rid21">21</a>]. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For individuals whose symptoms do not adequately improve with two to three months of phenylpropionic acid treatment, we next offer a fenamate (eg, <a class="drug drug_general" data-topicid="9601" href="/d/drug information/9601.html" rel="external">mefenamic acid</a> 500 mg initially followed by 250 mg every six hours, with treatment typically limited to three days)  (<a class="graphic graphic_table graphicRef71912" href="/d/graphic/71912.html" rel="external">table 3</a>). </p><p></p><p class="bulletIndent1">Since NSAIDs are given for only a few days to young, generally healthy persons, adverse effects tend to be less frequent than in other patient populations. General considerations regarding therapeutic use, drug interactions, and toxicities of NSAIDs are discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/7993.html" rel="external">"NSAIDs: Therapeutic use and variability of response in adults"</a> and  <a class="medical medical_review" href="/d/html/7991.html" rel="external">"Nonselective NSAIDs: Overview of adverse effects"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>COX-2 selective NSAIDs (coxibs)</strong> – The only COX-2 selective NSAID specifically studied and indicated for treatment of (primary) dysmenorrhea is <a class="drug drug_general" data-topicid="8847" href="/d/drug information/8847.html" rel="external">celecoxib</a>, although others are available. These drugs are more expensive than nonspecific NSAIDs but may be useful in individuals who are at high risk for NSAID-related gastroduodenal toxicity. However, most of these agents have either been withdrawn from the market or issued with black box warnings regarding the risk of serious adverse events. Given these risks and the availability of safe and effective alternatives (nonspecific NSAIDs, as discussed above), we do not use COX-2 inhibitors for treatment of primary dysmenorrhea. (See  <a class="medical medical_review" href="/d/html/7992.html" rel="external">"Overview of COX-2 selective NSAIDs"</a> and  <a class="medical medical_review" href="/d/html/7968.html" rel="external">"NSAIDs: Adverse cardiovascular effects"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Potential delay of ovulation</strong> – Because prostaglandins play an important role in ovulation, NSAIDs, particularly COX-2 inhibitors, can prevent or delay this process [<a href="#rid22">22-24</a>]. In fact, the negative effect of COX-2 inhibitors on ovulation is the basis of studies of these agents as potential emergency contraceptives [<a href="#rid25">25</a>]. Clinical studies examining the effects of various NSAIDs in normally cycling subjects have demonstrated mixed effects on ovulation [<a href="#rid26">26-30</a>]. </p><p></p><p class="bulletIndent1">Individuals taking NSAIDs and attempting to conceive can generally be reassured that NSAID therapy is unlikely to delay ovulation because these agents are only used at the time of menstruation. However, if a patient experiences difficulty conceiving, we suggest avoiding these drugs or reducing the dose, if possible, though the effect of such reduction is unproven [<a href="#rid31">31,32</a>].</p><p></p><p class="headingAnchor" id="H2573376967"><span class="h3">Acetaminophen (paracetamol)</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9242" href="/d/drug information/9242.html" rel="external">Acetaminophen</a> is a reasonable alternative for patients with medical contraindications to or intolerance of NSAIDs who desire pharmacotherapy for pain relief. Although the above meta-analysis reported NSAID treatment appeared more effective at reducing pain than acetaminophen based on data from three trials (OR 1.89, 95% CI 1.05-3.43), acetaminophen does not typically have adverse gastrointestinal side effects. A meta-analysis of self-care strategies used by young women (under age 25) with dysmenorrhea reported that nearly one-third used acetaminophen to treat their pain, but nearly one-half reported inadequate pain relief [<a href="#rid33">33</a>]. Studies evaluating acetaminophen in combination with either <a class="drug drug_general" data-topicid="9213" href="/d/drug information/9213.html" rel="external">caffeine</a> or <a class="drug drug_general" data-topicid="9508" href="/d/drug information/9508.html" rel="external">pamabrom</a> (a short-acting diuretic) have reported reduced pain [<a href="#rid34">34,35</a>]. We reserve acetaminophen trials for patients with NSAID intolerance who also prefer to avoid hormonal contraception.</p><p class="headingAnchor" id="H10"><span class="h2">Hormonal contraception</span><span class="headingEndMark"> — </span>For people with dysmenorrhea who either desire contraception or for whom use of a contraceptive is acceptable, we suggest treatment with an estrogen-progestin hormonal contraceptive (eg, combined estrogen-progestin oral pills, transdermal patches, or vaginal rings) or placement of a levonorgestrel-releasing intrauterine device as a first-line option. The choice of method is ultimately determined by the patient and based on preferences for dosing, cycle control, cost, availability, and side effects, among other variables. (See  <a class="medical medical_review" href="/d/html/5459.html" rel="external">"Contraception: Counseling and selection"</a>.)</p><p class="headingAnchor" id="H15853619"><span class="h3">Estrogen-progestin methods</span><span class="headingEndMark"> — </span>Estrogen-progestin contraceptives contain synthetic progestins that suppress ovulation and cause the endometrium to become thin over time. The thin endometrium contains relatively small amounts of arachidonic acid, the substrate for most prostaglandin synthesis. As a result of these changes in the endometrium, estrogen-progestin contraceptives reduce both uterine bleeding flow and uterine contractions occurring during flow, thereby decreasing dysmenorrhea. (See  <a class="medical medical_review" href="/d/html/7398.html" rel="external">"Combined estrogen-progestin oral contraceptives: Patient selection, counseling, and use"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Oral pills</strong> – Although limitations of contraceptive pill studies have included small sample sizes, limited comparative data, and inclusion of multiple treatment regimens, the body of evidence suggests that any combination oral estrogen-progestin contraceptive pill is likely to reduce dysmenorrhea. A meta-analysis of trials comparing estrogen-progestin contraceptive pills with placebo reported treatment benefit (pooled OR 2.01, 95% CI 1.32-3.08, seven trials) [<a href="#rid36">36</a>]. The meta-analysis also concluded pain relief was similar for pills with estrogen doses ≤35 mcg and &gt;35 mcg, and there was no clear difference in efficacy among the different pill preparations. Lower dose formulations (eg, 20 mcg of ethinyl estradiol) also appear to be effective at reducing pain [<a href="#rid37">37-42</a>]. While trials have reported better relief of menstrual symptoms with extended or continuous dosing compared with cyclic administration, all regimens appear to be effective for symptom relief [<a href="#rid43">43-45</a>]. For patients in whom conventional cyclic dosing (21 days of medication/7 days of placebo) of oral contraceptive formulation does not provide sufficient relief of dysmenorrhea, it is reasonable to change to a formulation with a reduced hormone-free interval (eg, a 24/4 formulation) or an extended cycle formulation. Cycle selection is ultimately determined by patient preference. At least one consensus guideline advises pill use to reduce dysmenorrhea [<a href="#rid46">46</a>]. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>(See  <a class="medical medical_review" href="/d/html/7398.html" rel="external">"Combined estrogen-progestin oral contraceptives: Patient selection, counseling, and use"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>(See  <a class="medical medical_review" href="/d/html/5423.html" rel="external">"Hormonal contraception for menstrual suppression", section on 'Combined estrogen-progestin methods'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Vaginal rings</strong> <strong>and</strong> <strong>transdermal patches </strong>– As transdermal and vaginal estrogen-progestin contraceptives are newer than oral contraceptives, few trials have evaluated their efficacy for treatment of primary dysmenorrhea or compared them with other therapies. The endometrial effects of estrogen-progestin contraceptives are similar regardless of the method of delivery; therefore, the route of administration should not significantly affect efficacy. (See  <a class="medical medical_review" href="/d/html/16682.html" rel="external">"Contraception: Hormonal contraceptive vaginal rings"</a> and  <a class="medical medical_review" href="/d/html/5425.html" rel="external">"Contraception: Transdermal contraceptive patches"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Ring versus pill</strong> – A review of 12 randomized trials comparing the contraceptive vaginal ring containing etonogestrel with oral contraceptives concluded both methods had a similar favorable impact on dysmenorrhea [<a href="#rid47">47</a>]. The proportion of participants reporting moderate or severe dysmenorrhea decreased similarly for both groups (contraceptive ring: 17.4 to 5.9 percent; oral contraception users: 19.0 to 6.4 percent) [<a href="#rid48">48</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Patch versus pill</strong> – In a randomized trial designed to evaluate contraceptive efficacy and cycle control in norelgestromin/ethinyl estradiol contraceptive patch and oral contraceptive pill users, dysmenorrhea was slightly more common among women assigned to the patch (13.3 versus 9.6 percent) [<a href="#rid48">48</a>]. Although statistically significant (p = 0.04), this difference may have been due to chance.</p><p></p><p class="headingAnchor" id="H15853989"><span class="h3">Progestin-only methods</span><span class="headingEndMark"> — </span>Since the progestin component of estrogen-progestin contraceptives induces the endometrial atrophy that leads to relief of dysmenorrhea, progestin-only contraceptives may be an effective treatment, but they have not been studied as extensively as estrogen-progestin contraceptives. Some side effects, particularly irregular bleeding, are more common with progestin-only methods than with estrogen-progestin contraceptives. An advantage of progestin-only contraceptives is that they can be safely used by individuals for whom contraceptive doses of estrogen are contraindicated. A disadvantage is that <a class="drug drug_general" data-topicid="10173" href="/d/drug information/10173.html" rel="external">norethindrone</a> progestin-only methods do not inhibit ovulation as consistently as estrogen-progestin contraceptives, which may be important when used for treatment of dysmenorrhea. While all of the methods below have some efficacy data for reducing dysmenorrhea, there are no comparative studies. Thus, selection of a treatment is based on patient preferences. (See  <a class="medical medical_review" href="/d/html/7398.html" rel="external">"Combined estrogen-progestin oral contraceptives: Patient selection, counseling, and use", section on 'Candidates'</a> and  <a class="medical medical_review" href="/d/html/5461.html" rel="external">"Contraception: Progestin-only pills (POPs)"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="104542" href="/d/drug information/104542.html" rel="external">Levonorgestrel</a><strong> (LNG)-releasing intrauterine devices (IUDs)</strong> – Use of the 20 mcg LNG-releasing IUD is associated with reductions in dysmenorrhea, in part because of the approximately 20 percent amenorrhea rate after one year of use [<a href="#rid49">49-55</a>]. The one-year amenorrhea rates are lower with the lower dose LNG-releasing IUDs (12 percent of LNG 19.5 users and 6 percent of LNG 14 users) [<a href="#rid56">56-58</a>]. (See  <a class="medical medical_review" href="/d/html/116579.html" rel="external">"Intrauterine contraception: Background and device types", section on 'Levonorgestrel IUD'</a>.)</p><p></p><p class="bulletIndent1">A systematic review reported that <a class="drug drug_general" data-topicid="104541" href="/d/drug information/104541.html" rel="external">LNG IUDs</a> have an efficacy similar to oral estrogen-progestin pills for relief of dysmenorrhea [<a href="#rid52">52</a>]. Other data come from studies of surrogate populations. In a randomized trial of women with pelvic pain related to endometriosis, the 20 mcg LNG IUD was as effective as depot gonadotropin-releasing hormone agonist for control of pelvic pain [<a href="#rid59">59</a>]. A noncomparative study of 29 symptomatic women with magnetic resonance imaging-diagnosed adenomyosis reported that placement of a 20 mcg LNG significantly reduced pain scores at three and six months [<a href="#rid60">60</a>]. </p><p></p><p class="bulletIndent1">By contrast, copper T380A IUD users experience increased dysmenorrhea, which is a leading cause of discontinuation during the first year of use. (See  <a class="medical medical_review" href="/d/html/5419.html" rel="external">"Intrauterine contraception: Candidates and device selection"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Implantable contraception</strong> – In a large three-year Chilean clinical trial assessing the safety and efficacy of the single-rod etonogestrel-releasing contraceptive, over three-quarters of participants who reported primary dysmenorrhea at baseline noted an improvement at the end of treatment, while only 4 percent reported new or worsened dysmenorrhea [<a href="#rid61">61</a>]. In another trial, the single-rod etonogestrel-releasing contraceptive was associated with a 68 percent reduction of dysmenorrhea, nonmenstrual pelvic pain, and dyspareunia in women with histologically proven endometriosis [<a href="#rid62">62</a>]. In an analysis of 11 clinical trials of women (n = 923) using the contraceptive implant, complete resolution was achieved in more than three-fourths of implant recipients who reported dysmenorrhea prior to implant placement [<a href="#rid63">63</a>]. (See  <a class="medical medical_review" href="/d/html/3266.html" rel="external">"Contraception: Etonogestrel implant"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Progestin-only pills (POPs)</strong> – POPs available in the United States include <a class="drug drug_general" data-topicid="10173" href="/d/drug information/10173.html" rel="external">norethindrone</a> 0.35 mg tablets and <a class="drug drug_general" data-topicid="121397" href="/d/drug information/121397.html" rel="external">drospirenone</a> 4 mg tablets. Although studies support progestin-only treatment for patients with secondary dysmenorrhea related to endometriosis, its efficacy for treating primary dysmenorrhea is less clear [<a href="#rid64">64-67</a>]. A major limitation is the unscheduled bleeding associated with POPs [<a href="#rid68">68</a>].</p><p></p><p class="bulletIndent1">Treatment with oral <a class="drug drug_general" data-topicid="10173" href="/d/drug information/10173.html" rel="external">norethindrone</a> acetate 5 mg tablets represents a high-dose progestin-only option that has a low rate of unscheduled bleeding. However, this medication is not labeled for contraception. A trial randomly assigned a total of 38 patients with primary dysmenorrhea to continuous norethindrone acetate 5 mg tablets or estrogen-progestin oral contraceptive pills (cyclic dosing fashion) [<a href="#rid67">67</a>]. At six months of follow-up, the reduction in dysmenorrhea was similar between the two groups. One concern with use of higher doses of norethindrone acetate (2.5 to 10 mg) is a possible increased risk of deep vein thrombosis (DVT) [<a href="#rid69">69</a>]. Potential mechanisms for elevated DVT risk include that norethindrone and norethindrone acetate are converted to ethinyl estradiol in small quantities and that norethindrone acetate may impact gene expression of coagulation factors [<a href="#rid70">70,71</a>]. Thus, active thromboembolism is listed as a relative contraindication to norethindrone acetate use [<a href="#rid72">72</a>]. (See  <a class="medical medical_review" href="/d/html/5461.html" rel="external">"Contraception: Progestin-only pills (POPs)"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Injectable contraception</strong> – Limited observational data suggest injectable depot <a class="drug drug_general" data-topicid="9600" href="/d/drug information/9600.html" rel="external">medroxyprogesterone acetate</a> is associated with reductions in dysmenorrhea [<a href="#rid73">73</a>]. One likely mechanism is the 50 percent amenorrhea rate that occurs after one year of use as a result of endometrial atrophy [<a href="#rid74">74</a>]. However, return of fertility may be delayed after discontinuation, so those who may want to become pregnant within the next one or two years are advised to choose a different method. (See  <a class="medical medical_review" href="/d/html/5468.html" rel="external">"Depot medroxyprogesterone acetate (DMPA): Formulations, patient selection and drug administration"</a>.)</p><p></p><p class="headingAnchor" id="H781610412"><span class="h1">SECOND-TIER</span></p><p class="headingAnchor" id="H2623182260"><span class="h2">Transcutaneous electrical nerve stimulation</span><span class="headingEndMark"> — </span>Transcutaneous electrical nerve stimulation (TENS) is a reasonable next step for patients with continued pain despite the interventions above. This nonpharmacologic treatment can be used in addition to nonhormonal and/or hormonal therapies. This modality is also an alternative for patients who cannot or prefer not to use medications. One minimally invasive TENS option is percutaneous tibial nerve stimulation (PTNS). The major limitation of PTNS treatment is the need for weekly treatments for 12 weeks in a row. The patient completes the treatment course and then symptoms are reassessed. Patients with adequate pain improvement then continue any treatments that they were previously using. TENS treatment can be repeated if symptoms recur. Patients who do not improve with TENS proceed to the next treatment option. (See  <a class="medical medical_review" href="/d/html/5435.html" rel="external">"Chronic pelvic pain in adult females: Treatment"</a>.) </p><p>In a meta-analysis comparing high-frequency TENS with placebo for primary dysmenorrhea, high-frequency TENS more effectively reduced pain (odds ratio [OR] 7.2, 95% CI 3.1-16.5, two trials, 106 women) [<a href="#rid75">75</a>]. However, pain relief from low-frequency TENS was similar to that of placebo (OR 1.76, 95% CI 0.60-5.09, two trials, 63 women). A subsequent trial of 134 patients with primary dysmenorrhea that compared TENS with sham TENS reported greater pain relief and duration of pain relief, reduction of <a class="drug drug_general" data-topicid="8547" href="/d/drug information/8547.html" rel="external">ibuprofen</a> with active TENS, but similar outcomes in quality of life [<a href="#rid76">76</a>]. The degree of pain relief obtained with TENS alone is less than that from drugs; however, some patients may be able to lower their analgesic dose with combined therapy. TENS may also be combined with topical heat therapy with good effect [<a href="#rid77">77</a>].</p><p>TENS is hypothesized to have two effects: (1) it raises the threshold for pain signals from uterine hypoxia and hypercontractility by sending a volley of afferent impulses through the large diameter sensory fibers of the same nerve root, resulting in lower perception of painful uterine signals, and (2) it stimulates release of endorphins from the peripheral nerves and the spinal cord [<a href="#rid78">78</a>]. Intrauterine pressure studies indicate that TENS therapy had no effect on uterine contractile activity [<a href="#rid79">79</a>].</p><p class="headingAnchor" id="H1694263877"><span class="h2">Empiric GnRH analog therapy</span><span class="headingEndMark"> — </span>While we generally base our decision for gonadotropin-releasing hormone (GnRH) analog treatment on the findings at laparoscopy, there is a role for empiric treatment, including: </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patients with persistent dysmenorrhea who desire to avoid surgery</strong> – One option is to make a presumptive diagnosis of endometriosis and offer these women treatment with a GnRH analog. GnRH agonists include <a class="drug drug_general" data-topicid="9673" href="/d/drug information/9673.html" rel="external">nafarelin</a> (200 mcg intranasal spray twice per day) or <a class="drug drug_general" data-topicid="9549" href="/d/drug information/9549.html" rel="external">leuprolide</a> acetate depot (3.75 mg intramuscularly every four weeks) [<a href="#rid80">80</a>]. However, treatment with these agents is often limited by side effects. An alternative option is treatment with a GnRH antagonist, such as <a class="drug drug_general" data-topicid="118522" href="/d/drug information/118522.html" rel="external">elagolix</a>, which is orally dosed. If the pain significantly improves or resolves with either agonist or antagonist therapy, then endometriosis is likely, although not confirmed. (See  <a class="medical medical_review" href="/d/html/7383.html" rel="external">"Endometriosis: Treatment of pelvic pain", section on 'Agonists'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patients with persistent pain and negative laparoscopy</strong> – If laparoscopy is negative and the patient has previously failed both hormonal contraception and nonsteroidal anti-inflammatory drugs, we would try a three-month course of a GnRH agonist, such as <a class="drug drug_general" data-topicid="9673" href="/d/drug information/9673.html" rel="external">nafarelin</a> or <a class="drug drug_general" data-topicid="9549" href="/d/drug information/9549.html" rel="external">leuprolide</a>, since endometriosis may have been missed. Even in the hands of experienced laparoscopists, an accurate diagnosis of endometriosis can be difficult since the disease is often microscopic and presents visually with a variety of atypical lesions. For patients who do not tolerate or desire GnRH agonist treatment, use of a GnRH antagonist is a reasonable option, although supporting data are limited as it is a newer treatment. (See  <a class="medical medical_review" href="/d/html/7383.html" rel="external">"Endometriosis: Treatment of pelvic pain", section on 'Gonadotropin-releasing hormone (GnRH) analogs'</a>.)</p><p></p><p>Limitations of GnRH analog treatment include menopause-like side effects, cost, and loss of bone density with long-term use. For these reasons, we generally reserve GnRH agonist/antagonist treatment for individuals with confirmed endometriosis. Alternatively, and if not already tried, continuous or extended-cycle estrogen-progestin contraception, a levonorgestrel-releasing intrauterine device, continuous <a class="drug drug_general" data-topicid="10173" href="/d/drug information/10173.html" rel="external">norethindrone</a> acetate tablets, or depot <a class="drug drug_general" data-topicid="9600" href="/d/drug information/9600.html" rel="external">medroxyprogesterone acetate</a> can be used in this setting. These agents are more affordable and safer over long-term use than GnRH analogs. (See  <a class="medical medical_review" href="/d/html/7416.html" rel="external">"Endometriosis: Long-term treatment with gonadotropin-releasing hormone agonists"</a>.)</p><p class="headingAnchor" id="H941578640"><span class="h1">ROLE OF LAPAROSCOPY</span><span class="headingEndMark"> — </span>We offer diagnostic laparoscopy for individuals with dysmenorrhea who have not had adequate relief after three to six months of nonsteroidal anti-inflammatory drugs and/or hormonal contraception [<a href="#rid81">81</a>]. Studies have reported that 70 to 80 percent of women with persistent pelvic pain are diagnosed with endometriosis at the time of laparoscopy [<a href="#rid80">80,82-86</a>]. However, the role and timing of laparoscopy depends on patient and clinician preference. As noted above, some patients strongly wish to avoid surgery, in which case empiric treatment with a gonadotropin-releasing hormone agonist/antagonist is a reasonable alternative. (See <a class="local">'Empiric GnRH analog therapy'</a> above.)</p><p class="headingAnchor" id="H1868868406"><span class="h1">SURGERY FOR REFRACTORY DYSMENORRHEA</span></p><p class="headingAnchor" id="H3302256660"><span class="h2">Endometrial ablation</span><span class="headingEndMark"> — </span>Endometrial ablation appears to be helpful for select patients not desiring future childbearing whose dysmenorrhea is related to heavy menstrual bleeding. In a retrospective cohort study of 144 patients who underwent endometrial ablation, nearly one-half (48/100) of the women with preoperative dysmenorrhea had resolution of their symptoms after ablation [<a href="#rid87">87</a>]. Patients who had a reduction in menstrual flow following ablation were more likely to report resolution of their dysmenorrhea. </p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/3316.html" rel="external">"Overview of endometrial ablation"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/3263.html" rel="external">"Abnormal uterine bleeding in nonpregnant reproductive-age patients: Terminology, evaluation, and approach to diagnosis"</a>.)</p><p></p><p class="headingAnchor" id="H2834788343"><span class="h2">Hysterectomy</span><span class="headingEndMark"> — </span>We reserve hysterectomy for patients who have completed childbearing and have inadequate response to the above therapies. (See  <a class="medical medical_review" href="/d/html/3272.html" rel="external">"Hysterectomy (benign indications): Selection of surgical route"</a>.)</p><p class="headingAnchor" id="H577870073"><span class="h1">SUPPORTIVE THERAPIES</span><span class="headingEndMark"> — </span>While behavioral counseling and diet/dietary supplements show some promise for reducing dysmenorrhea, the supporting evidence is weak to limited. Interested patients are welcome to add these approaches to their treatment regimens, but safety and efficacy are inadequately studied.</p><p class="headingAnchor" id="H1878742797"><span class="h2">Behavioral counseling</span><span class="headingEndMark"> — </span>Behavioral counseling teaches patients strategies to modify the way they think about their pain (eg, desensitization-based procedures, hypnotherapy, imagery, coping strategies) and attempts to modify their response to pain (eg, biofeedback, electromyographic training, Lamaze exercises, relaxation training). There is no high-quality evidence to support or refute use of these modalities; two different reviews concluded some patients may be helped by them [<a href="#rid88">88,89</a>]. We find behavioral counseling a helpful adjunct to exercise and pharmacologic therapy in motivated patients.</p><p class="headingAnchor" id="H562146451"><span class="h2">Physiotherapy treatment</span><span class="headingEndMark"> — </span>Physiotherapy and activity-based therapies may be helpful and carry little risk. A meta-analysis evaluating use of isometric exercises, massage therapy, yoga, electrotherapy, connective tissue manipulation, stretching, kinesio tape, progressive relaxation exercises, and aerobic dance found some support for the use of these modalities but noted that the evidence was of low quality [<a href="#rid90">90</a>]. A similar literature review of therapeutic taping reported some improvement in anxiety but limited other benefits [<a href="#rid91">91</a>]. A randomized controlled trial of connective tissue manipulation (CTM) in primary dysmenorrhea reported a reduction in the perception of pain but no reduction in the use of other analgesics [<a href="#rid92">92</a>]. Given the paucity of high-quality data, we see these modalities as supplemental therapies for interested patients.</p><p class="headingAnchor" id="H3552246903"><span class="h2">Complementary or alternative medicine</span><span class="headingEndMark"> — </span>There is limited evidence from controlled trials to support the use of complementary or alternative medicine for treatment of dysmenorrhea. However, as the risk from these interventions is also low, patients who wish to use them may reasonably do so.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Acupuncture or acupressure</strong> – Although multiple studies of acupuncture for treatment of dysmenorrhea have been published, these studies are generally of low quality and vary widely in design. As a result of study heterogeneity, a 2016 meta-analysis of 42 trials on acupuncture or acupressure was unable to determine if acupuncture or acupressure was effective in treating primary dysmenorrhea [<a href="#rid93">93</a>]. A 2018 meta-analysis of 49 trials concluded that, while the available data were mostly of low quality, acupuncture might reduce dysmenorrhea symptoms compared with no treatment or nonsteroidal anti-inflammatory drug therapy [<a href="#rid94">94</a>]. A separate trial including 221 women comparing smartphone app acupressure self-treatment with usual care reported reduced menstrual pain with self-acupressure and noted an improved response over time (three to six months) [<a href="#rid95">95</a>]. Small but significant improvements were noted in the worst pain intensity, number of days with pain, and proportion of patients using pain medication. Study limitations include an open-label design and lack of an active comparator group. Nonetheless, this trial highlights the benefits of studying symptom response over more than one cycle in order to optimally assess treatment efficacy. A trial that compared dry needling of the rectus abdominis with sham needling or no treatment reported greater reductions in reported pain and medication use by patients who received the active treatment [<a href="#rid96">96</a>]. One meta-analysis noted the absence of safety data in most of these studies, concluding that there is not enough evidence to support the safety of simple needling in the treatment of primary dysmenorrhea [<a href="#rid97">97</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other</strong> – A systematic review of four trials of high-velocity, low-amplitude spinal manipulation reported the technique was no more effective than sham manipulation for the treatment of primary dysmenorrhea, although it was possibly more effective than no treatment [<a href="#rid98">98</a>].</p><p></p><p class="bulletIndent1">One small trial reported Japanese herbal combinations were more effective for reducing pain than placebo [<a href="#rid99">99</a>]. In a systematic review of 39 randomized trials of Chinese herbal medicine for treatment of primary dysmenorrhea, this approach appeared to be promising compared with other therapies, but no firm conclusions could be made due to poor methodologic quality of the available trials [<a href="#rid100">100</a>]. A randomized controlled parallel-group study demonstrated comparable pain response for acupressure and motor imagery-focused pelvic floor exercise, but the sample size and the clinical effects reported were small [<a href="#rid101">101</a>].</p><p></p><p class="headingAnchor" id="H3405623724"><span class="h2">Diet and vitamins</span><span class="headingEndMark"> — </span>A variety of dietary changes and vitamin therapies have been reported to reduce the severity of menstrual pain, but data are limited to a few small studies. Although the limited available data appear promising, we would like to see confirmatory data from additional trials before suggesting these interventions for our patients [<a href="#rid102">102</a>]. Interventions that have been associated with some reduction in dysmenorrhea include:</p><p class="bulletIndent1"><span class="glyph">●</span>Low fat vegetarian diet [<a href="#rid103">103</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Increased dairy intake [<a href="#rid104">104</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="10049" href="/d/drug information/10049.html" rel="external">Vitamin E</a> (500 units per day or 200 units twice per day, beginning two days before menses and continuing through the first three days of bleeding) [<a href="#rid105">105,106</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Vitamin B1 (100 mg daily), <a class="drug drug_general" data-topicid="9839" href="/d/drug information/9839.html" rel="external">vitamin B6</a> (200 mg daily), and fish oil supplement (1080 mg eicosapentaenoic acid, 720 mg docosahexaenoic acid, and 1.5 mg <a class="drug drug_general" data-topicid="10049" href="/d/drug information/10049.html" rel="external">vitamin E</a>) were each more effective for reducing pain than placebo [<a href="#rid99">99</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A single large dose of<strong> </strong><a class="drug drug_general" data-topicid="10117" href="/d/drug information/10117.html" rel="external">vitamin D3</a> (oral, 300,000 international units/1 mL) given five days prior to the expected first day of the menstrual cycle, although the safety of this approach is unclear [<a href="#rid107">107,108</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Consumption of 750 to 2000 mg of ginger powder on days 1 to 3 of the menstrual cycle [<a href="#rid109">109-112</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Dietary supplementation with omega-3 polyunsaturated fatty acids has shown limited effects but a paradoxical reduction in effect with increasing doses and patient age [<a href="#rid113">113</a>].</p><p></p><p class="headingAnchor" id="H28153582"><span class="h1">LIMITATIONS OF AVAILABLE DATA</span><span class="headingEndMark"> — </span>A placebo effect is particularly strong in primary dysmenorrhea trials, especially in the first month of treatment. However, the effects of placebo treatment appear to fade quickly. This was illustrated in a study in which placebo therapy was associated with self-reported improvement in symptoms in the first, second, third, and fourth months of treatment in 84, 29, 16, and 10 percent of women, respectively [<a href="#rid114">114</a>]. By comparison, active treatment with nonsteroidal anti-inflammatory drugs produced an 80 to 86 percent response rate that was maintained throughout the four months of treatment. These results underscore that, optimally, treatment of primary dysmenorrhea is informed by prospective, double-blind trials in which treatment is administered and tracked over several cycles.</p><p class="headingAnchor" id="H6106857"><span class="h1">INEFFECTIVE OR UNPROVEN TREATMENTS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Nerve transection procedures</strong> – There is insufficient evidence to recommend nerve transection procedures, including laparoscopic uterine nerve ablation and presacral neurectomy, for relief of dysmenorrhea [<a href="#rid115">115-117</a>]. There may be a role for presacral neurectomy in patients with chronic midline pelvic pain associated with endometriosis [<a href="#rid118">118</a>]. The use of these procedures for patients with endometriosis and chronic pelvic pain is described elsewhere.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>(See  <a class="medical medical_review" href="/d/html/7383.html" rel="external">"Endometriosis: Treatment of pelvic pain", section on 'Nerve transection'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>(See  <a class="medical medical_review" href="/d/html/5435.html" rel="external">"Chronic pelvic pain in adult females: Treatment", section on 'When to perform additional surgical procedures aimed to reduce pain'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Aromatase inhibitors</strong> – While there are some data supporting use of aromatase inhibitors (AI) in patients with secondary dysmenorrhea and pelvic pain related to endometriosis, these agents are not typically used for patients with primary dysmenorrhea. AI treatment is generally reserved for those with severe, refractory endometriosis-related pain [<a href="#rid119">119,120</a>]. (See  <a class="medical medical_review" href="/d/html/7383.html" rel="external">"Endometriosis: Treatment of pelvic pain", section on 'Aromatase inhibitors'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Tocolytics</strong> – Primary dysmenorrhea is caused by excessive uterine muscle contractions. Thus, agents that block uterine contractility (ie, tocolytics) may be effective in the treatment of this disorder. Nitric oxide, <a class="drug drug_general" data-topicid="9706" href="/d/drug information/9706.html" rel="external">nitroglycerin</a>, and calcium channel blockers all have tocolytic effects and are under investigation as potential therapies of dysmenorrhea. We do not currently use any of these drugs for treatment of primary dysmenorrhea.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9706" href="/d/drug information/9706.html" rel="external">Nitroglycerin</a><strong> (glyceryl trinitrate)</strong> – A multinational, double-blind, placebo-controlled, randomized crossover trial demonstrated that nitroglycerin (glyceryl trinitrate) patches (0.1 mg per hour) were effective for reduction of dysmenorrhea [<a href="#rid121">121</a>]. However, in another trial that compared nitroglycerin (glyceryl trinitrate) with a nonsteroidal anti-inflammatory drug (NSAID; <a class="drug drug_general" data-topicid="9348" href="/d/drug information/9348.html" rel="external">diclofenac</a> 50 mg daily) in the treatment of primary dysmenorrhea, nitroglycerin (glyceryl trinitrate) was less effective than the NSAID and was associated with more side effects, particularly headache [<a href="#rid122">122</a>]. Although nitroglycerin (glyceryl trinitrate) is effective in reducing pain, low tolerability limits its use [<a href="#rid123">123</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9700" href="/d/drug information/9700.html" rel="external">Nifedipine</a> – Nifedipine (single oral dose of 20 to 40 mg) has been documented to reduce the intensity of uterine contractions [<a href="#rid124">124</a>] and relieve pain in individuals with primary dysmenorrhea, although supporting data are limited by small numbers of study participants [<a href="#rid124">124-127</a>]. In one study including 12 women with severe dysmenorrhea, nifedipine (single oral dose of 30 mg) relieved dysmenorrhea within 60 minutes in the majority of women treated [<a href="#rid125">125</a>]. In another study, nifedipine given to 40 women with dysmenorrhea resulted in moderate to good pain reduction in 36 patients but was associated with a moderate rate of side effects (facial flushing, tachycardia, headache) [<a href="#rid126">126</a>]. Serious cardiovascular events have occurred when short-acting calcium channel blockers were given to patients with hypertension. (See  <a class="medical medical_review" href="/d/html/3832.html" rel="external">"Major side effects and safety of calcium channel blockers"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Magnesium</strong> – Three small randomized trials found that magnesium was more effective than placebo for relief of dysmenorrhea and was well-tolerated [<a href="#rid99">99</a>]. However, the small size of the trials, high dropout rates, and varying designs precluded a definite recommendation for use of magnesium or the optimum dose or regimen.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Phosphodiesterase inhibitors</strong> – By inhibiting phosphodiesterase, <a class="drug drug_general" data-topicid="9643" href="/d/drug information/9643.html" rel="external">sildenafil</a> enhances the vasodilatory effects of nitric oxide, facilitating myometrial blood flow, and thus reducing primary dysmenorrhea. Oral medications that enhance nitric oxide's relaxation of myometrial cells can relieve prostaglandin-associated menstrual pain, but side effects associated with this route of administration have precluded clinical use for primary dysmenorrhea. Vaginal administration has been investigated. In a small randomized, double-blind trial, the efficacy of a vaginal preparation of sildenafil citrate (100 mg single dose) was assessed in 62 women with primary dysmenorrhea. Vaginal sildenafil reduced primary dysmenorrhea more than placebo. However, the study was not able to meet its recruitment goals, and accordingly, the findings were not conclusive [<a href="#rid128">128</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Anticholinergic agents</strong> – <a class="drug drug_general" data-topicid="9915" href="/d/drug information/9915.html" rel="external">Scopolamine</a> (hyoscine) butylbromide and related drugs that relax smooth muscle through muscarinic receptors can be used to treat dysmenorrhea [<a href="#rid129">129,130</a>]. However, supporting data are sparse, and medication use is often limited by side effects, which typically include dry mouth, constipation, and dizziness [<a href="#rid131">131</a>]. </p><p></p><p class="headingAnchor" id="H2386833573"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/118171.html" rel="external">"Society guideline links: Dysmenorrhea"</a>.)</p><p class="headingAnchor" id="H18"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/d/html/15423.html" rel="external">"Patient education: Painful periods (The Basics)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topics (see  <a class="medical medical_patient" href="/d/html/8389.html" rel="external">"Patient education: Painful menstrual periods (dysmenorrhea) (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H19"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment goals</strong> – The goal of treatment is to provide adequate relief of pain. At a minimum, pain relief should be sufficient to allow patients to perform most, if not all, of their usual activities. Treatment of primary dysmenorrhea can be initiated empirically. (See <a class="local">'Our approach'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Nonpharmacologic interventions</strong> – Low-risk baseline, nonpharmacologic interventions with documented efficacy include exercise and heat application  (<a class="graphic graphic_algorithm graphicRef126057" href="/d/graphic/126057.html" rel="external">algorithm 1</a>). As these are low cost and low risk, we discuss these treatments with all dysmenorrhea patients. (See <a class="local">'Baseline interventions'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>First tier medication therapy</strong> – For patients with inadequate response to baseline interventions, nonsteroidal anti-inflammatory drugs (NSAIDs) and hormonal contraceptives are the mainstays of therapy  (<a class="graphic graphic_algorithm graphicRef126057" href="/d/graphic/126057.html" rel="external">algorithm 1</a>). There is no evidence favoring one of these medication classes over the other. If treatment with one of the modalities fails or is inadequate after three months, we try a course of treatment with the other modality. Treatment with both NSAIDs and hormonal contraceptives may be effective in individuals who remain symptomatic on either drug alone. (See <a class="local">'First-tier'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Nonsteroidal anti-inflammatory drugs (NSAIDs)</strong> – For individuals who desire analgesic medications for treatment of dysmenorrhea, we suggest NSAIDs for first-line therapy (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). NSAID therapy is more effective than placebo and <a class="drug drug_general" data-topicid="9242" href="/d/drug information/9242.html" rel="external">acetaminophen</a> and is generally well tolerated. We start with a phenylpropionic acid derivative, such as <a class="drug drug_general" data-topicid="8547" href="/d/drug information/8547.html" rel="external">ibuprofen</a>, at the upper end of the dose range (400 to 600 mg orally every six hours <strong>or</strong> 800 mg every 8 hours, to be taken with onset of menses for duration of typical symptoms). If this does not result in adequate pain relief, we switch to a fenamate, such as <a class="drug drug_general" data-topicid="9601" href="/d/drug information/9601.html" rel="external">mefenamic acid</a> (500 mg loading dose, 250 mg every six hours for three days). (See <a class="local">'Nonsteroidal anti-inflammatory drugs'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Estrogen-progestin contraceptives</strong> – For individuals with dysmenorrhea who either desire contraception or for whom use of a contraceptive is acceptable, we suggest treatment with an estrogen-progestin hormonal contraceptive for first-line therapy (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). There are no data that one dose or formulation is more effective than another. The choice depends upon patient preferences for dosing, cycle control, cost, availability, and side effects, among other variables. (See <a class="local">'Hormonal contraception'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Progestin-only contraceptives</strong> – Progestin-only contraceptives have been less well studied for the treatment of dysmenorrhea compared with estrogen-progestin contraceptives, except for the 20 mcg <a class="drug drug_general" data-topicid="104541" href="/d/drug information/104541.html" rel="external">levonorgestrel IUD</a>. This IUD is associated with reductions in dysmenorrhea. (See <a class="local">'Progestin-only methods'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Second tier medical management</strong> – For those with dysmenorrhea who do not respond to three to six cycles of NSAIDs and hormonal contraception, second-tier therapies include transcutaneous electrical nerve stimulation and gonadotropin-releasing hormone agonists/antagonists. The time required for treatment, side effects, and cost limit the use of these options. Patients who decline these treatments or do not improve then generally proceed with laparoscopy. (See <a class="local">'Second-tier'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Additional options</strong> </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Role of laparoscopy</strong> – Patients whose symptoms persist are likely to have a gynecologic disease, such as endometriosis, causing their pain. We offer diagnostic laparoscopy to these patients and base subsequent treatment decisions on findings at laparoscopy. (See <a class="local">'Role of laparoscopy'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Endometrial ablation</strong> – For patients whose dysmenorrhea persists in the setting of heavy menstrual bleeding, endometrial ablation may be an option. Hysterectomy is the definitive surgical therapy in patients who have completed childbearing. (See <a class="local">'Surgery for refractory dysmenorrhea'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Supportive therapies</strong> – Although the evidence for supportive therapies such as behavioral counseling, complementary medicine, and dietary changes is weak, these interventions are unlikely to be harmful when used in moderation (for supplements in particular). Interested patients can add these approaches to their other treatment regimens at any time. (See <a class="local">'Supportive therapies'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Schoep ME, Adang EMM, Maas JWM, et al. Productivity loss due to menstruation-related symptoms: a nationwide cross-sectional survey among 32 748 women. BMJ Open 2019; 9:e026186.</a></li><li><a class="nounderline abstract_t">Matthewman G, Lee A, Kaur JG, Daley AJ. Physical activity for primary dysmenorrhea: a systematic review and meta-analysis of randomized controlled trials. Am J Obstet Gynecol 2018; 219:255.e1.</a></li><li><a class="nounderline abstract_t">Yang NY, Kim SD. Effects of a Yoga Program on Menstrual Cramps and Menstrual Distress in Undergraduate Students with Primary Dysmenorrhea: A Single-Blind, Randomized Controlled Trial. J Altern Complement Med 2016; 22:732.</a></li><li><a class="nounderline abstract_t">Kannan P, Chapple CM, Miller D, et al. Effectiveness of a treadmill-based aerobic exercise intervention on pain, daily functioning, and quality of life in women with primary dysmenorrhea: A randomized controlled trial. Contemp Clin Trials 2019; 81:80.</a></li><li><a class="nounderline abstract_t">Samy A, Zaki SS, Metwally AA, et al. The Effect of Zumba Exercise on Reducing Menstrual Pain in Young Women with Primary Dysmenorrhea: A Randomized Controlled Trial. J Pediatr Adolesc Gynecol 2019; 32:541.</a></li><li><a class="nounderline abstract_t">Chen HM, Hu HM. Randomized Trial of Modified Stretching Exercise Program for Menstrual Low Back Pain. West J Nurs Res 2019; 41:238.</a></li><li><a class="nounderline abstract_t">Dehnavi ZM, Jafarnejad F, Kamali Z. The Effect of aerobic exercise on primary dysmenorrhea: A clinical trial study. J Educ Health Promot 2018; 7:3.</a></li><li><a class="nounderline abstract_t">Yonglitthipagon P, Muansiangsai S, Wongkhumngern W, et al. Effect of yoga on the menstrual pain, physical fitness, and quality of life of young women with primary dysmenorrhea. J Bodyw Mov Ther 2017; 21:840.</a></li><li><a class="nounderline abstract_t">Kannan P, Cheung KK, Lau BW. Does aerobic exercise induced-analgesia occur through hormone and inflammatory cytokine-mediated mechanisms in primary dysmenorrhea? Med Hypotheses 2019; 123:50.</a></li><li><a class="nounderline abstract_t">Akin MD, Weingand KW, Hengehold DA, et al. Continuous low-level topical heat in the treatment of dysmenorrhea. Obstet Gynecol 2001; 97:343.</a></li><li><a class="nounderline abstract_t">Akin M, Price W, Rodriguez G Jr, et al. Continuous, low-level, topical heat wrap therapy as compared to acetaminophen for primary dysmenorrhea. J Reprod Med 2004; 49:739.</a></li><li><a class="nounderline abstract_t">Navvabi Rigi S, Kermansaravi F, Navidian A, et al. Comparing the analgesic effect of heat patch containing iron chip and ibuprofen for primary dysmenorrhea: a randomized controlled trial. BMC Womens Health 2012; 12:25.</a></li><li><a class="nounderline abstract_t">Lee B, Hong SH, Kim K, et al. Efficacy of the device combining high-frequency transcutaneous electrical nerve stimulation and thermotherapy for relieving primary dysmenorrhea: a randomized, single-blind, placebo-controlled trial. Eur J Obstet Gynecol Reprod Biol 2015; 194:58.</a></li><li><a class="nounderline abstract_t">Marjoribanks J, Ayeleke RO, Farquhar C, Proctor M. Nonsteroidal anti-inflammatory drugs for dysmenorrhoea. Cochrane Database Syst Rev 2015; 2015:CD001751.</a></li><li><a class="nounderline abstract_t">Owen PR. Prostaglandin synthetase inhibitors in the treatment of primary dysmenorrhea. Outcome trials reviewed. Am J Obstet Gynecol 1984; 148:96.</a></li><li><a class="nounderline abstract_t">Zhang WY, Li Wan Po A. Efficacy of minor analgesics in primary dysmenorrhoea: a systematic review. Br J Obstet Gynaecol 1998; 105:780.</a></li><li><a class="nounderline abstract_t">Zahradnik HP, Hanjalic-Beck A, Groth K. Nonsteroidal anti-inflammatory drugs and hormonal contraceptives for pain relief from dysmenorrhea: a review. Contraception 2010; 81:185.</a></li><li><a class="nounderline abstract_t">Budoff PW. Use of mefenamic acid in the treatment of primary dysmenorrhea. JAMA 1979; 241:2713.</a></li><li><a class="nounderline abstract_t">Milsom I, Minic M, Dawood MY, et al. Comparison of the efficacy and safety of nonprescription doses of naproxen and naproxen sodium with ibuprofen, acetaminophen, and placebo in the treatment of primary dysmenorrhea: a pooled analysis of five studies. Clin Ther 2002; 24:1384.</a></li><li><a class="nounderline abstract_t">Feng X, Wang X. Comparison of the efficacy and safety of non-steroidal anti-inflammatory drugs for patients with primary dysmenorrhea: A network meta-analysis. Mol Pain 2018; 14:1744806918770320.</a></li><li class="breakAll">Motrin ibuprofen tables. US Food and Drug Administration (FDA) approved product information. (Available online at https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/017463s105lbl.pdf).</li><li><a class="nounderline abstract_t">Pall M, Fridén BE, Brännström M. Induction of delayed follicular rupture in the human by the selective COX-2 inhibitor rofecoxib: a randomized double-blind study. Hum Reprod 2001; 16:1323.</a></li><li><a class="nounderline abstract_t">Duffy DM, VandeVoort CA. Maturation and fertilization of nonhuman primate oocytes are compromised by oral administration of a cyclooxygenase-2 inhibitor. Fertil Steril 2011; 95:1256.</a></li><li><a class="nounderline abstract_t">Bata MS, Al-Ramahi M, Salhab AS, et al. Delay of ovulation by meloxicam in healthy cycling volunteers: A placebo-controlled, double-blind, crossover study. J Clin Pharmacol 2006; 46:925.</a></li><li><a class="nounderline abstract_t">Jesam C, Salvatierra AM, Schwartz JL, Croxatto HB. Suppression of follicular rupture with meloxicam, a cyclooxygenase-2 inhibitor: potential for emergency contraception. Hum Reprod 2010; 25:368.</a></li><li><a class="nounderline abstract_t">Uhler ML, Hsu JW, Fisher SG, Zinaman MJ. The effect of nonsteroidal anti-inflammatory drugs on ovulation: a prospective, randomized clinical trial. Fertil Steril 2001; 76:957.</a></li><li><a class="nounderline abstract_t">Toppozada M, El-Abd M, El-Sokkary H, El-Rahman HA. Effect of a prostaglandin inhibitor of human ovulation. Singapore J Obstet Gynecol 1979; 10:42.</a></li><li><a class="nounderline abstract_t">Lundström V, Landgren BM, Eneroth P, Johannisson E. The effect of a prostaglandin synthetase inhibitor on the hormonal profile and the endometrium in women. Acta Obstet Gynecol Scand Suppl 1983; 113:77.</a></li><li><a class="nounderline abstract_t">Athanasiou S, Bourne TH, Khalid A, et al. Effects of indomethacin on follicular structure, vascularity, and function over the periovulatory period in women. Fertil Steril 1996; 65:556.</a></li><li><a class="nounderline abstract_t">Killick S, Elstein M. Pharmacologic production of luteinized unruptured follicles by prostaglandin synthetase inhibitors. Fertil Steril 1987; 47:773.</a></li><li><a class="nounderline abstract_t">Norman RJ. Reproductive consequences of COX-2 inhibition. Lancet 2001; 358:1287.</a></li><li><a class="nounderline abstract_t">Norman RJ, Wu R. The potential danger of COX-2 inhibitors. Fertil Steril 2004; 81:493.</a></li><li><a class="nounderline abstract_t">Armour M, Parry K, Al-Dabbas MA, et al. Self-care strategies and sources of knowledge on menstruation in 12,526 young women with dysmenorrhea: A systematic review and meta-analysis. PLoS One 2019; 14:e0220103.</a></li><li><a class="nounderline abstract_t">Ali Z, Burnett I, Eccles R, et al. Efficacy of a paracetamol and caffeine combination in the treatment of the key symptoms of primary dysmenorrhoea. Curr Med Res Opin 2007; 23:841.</a></li><li><a class="nounderline abstract_t">Di Girolamo G, Sánchez AJ, De Los Santos AR, González CD. Is acetaminophen, and its combination with pamabrom, an effective therapeutic option in primary dysmenorrhoea? Expert Opin Pharmacother 2004; 5:561.</a></li><li><a class="nounderline abstract_t">Wong CL, Farquhar C, Roberts H, Proctor M. Oral contraceptive pill for primary dysmenorrhoea. Cochrane Database Syst Rev 2009; :CD002120.</a></li><li><a class="nounderline abstract_t">Petraglia F, Parke S, Serrani M, et al. Estradiol valerate plus dienogest versus ethinylestradiol plus levonorgestrel for the treatment of primary dysmenorrhea. Int J Gynaecol Obstet 2014; 125:270.</a></li><li><a class="nounderline abstract_t">Davis AR, Westhoff C, O'Connell K, Gallagher N. Oral contraceptives for dysmenorrhea in adolescent girls: a randomized trial. Obstet Gynecol 2005; 106:97.</a></li><li><a class="nounderline abstract_t">Callejo J, Díaz J, Ruiz A, García RM. Effect of a low-dose oral contraceptive containing 20 microg ethinylestradiol and 150 microg desogestrel on dysmenorrhea. Contraception 2003; 68:183.</a></li><li><a class="nounderline abstract_t">Winkler UH, Ferguson H, Mulders JA. Cycle control, quality of life and acne with two low-dose oral contraceptives containing 20 microg ethinylestradiol. Contraception 2004; 69:469.</a></li><li><a class="nounderline abstract_t">Endrikat J, Jaques MA, Mayerhofer M, et al. A twelve-month comparative clinical investigation of two low-dose oral contraceptives containing 20 micrograms ethinylestradiol/75 micrograms gestodene and 20 micrograms ethinylestradiol/150 micrograms desogestrel, with respect to efficacy, cycle control and tolerance. Contraception 1995; 52:229.</a></li><li><a class="nounderline abstract_t">Hendrix SL, Alexander NJ. Primary dysmenorrhea treatment with a desogestrel-containing low-dose oral contraceptive. Contraception 2002; 66:393.</a></li><li><a class="nounderline abstract_t">Edelman AB, Gallo MF, Jensen JT, et al. Continuous or extended cycle vs. cyclic use of combined oral contraceptives for contraception. Cochrane Database Syst Rev 2005; :CD004695.</a></li><li><a class="nounderline abstract_t">Machado RB, de Melo NR, Maia H Jr. Bleeding patterns and menstrual-related symptoms with the continuous use of a contraceptive combination of ethinylestradiol and drospirenone: a randomized study. Contraception 2010; 81:215.</a></li><li><a class="nounderline abstract_t">Sulak PJ, Kuehl TJ, Ortiz M, Shull BL. Acceptance of altering the standard 21-day/7-day oral contraceptive regimen to delay menses and reduce hormone withdrawal symptoms. Am J Obstet Gynecol 2002; 186:1142.</a></li><li><a class="nounderline abstract_t">Burnett M, Lemyre M. No. 345-Primary Dysmenorrhea Consensus Guideline. J Obstet Gynaecol Can 2017; 39:585.</a></li><li><a class="nounderline abstract_t">Roumen FJ. The contraceptive vaginal ring compared with the combined oral contraceptive pill: a comprehensive review of randomized controlled trials. Contraception 2007; 75:420.</a></li><li><a class="nounderline abstract_t">Audet MC, Moreau M, Koltun WD, et al. Evaluation of contraceptive efficacy and cycle control of a transdermal contraceptive patch vs an oral contraceptive: a randomized controlled trial. JAMA 2001; 285:2347.</a></li><li><a class="nounderline abstract_t">Varma R, Sinha D, Gupta JK. Non-contraceptive uses of levonorgestrel-releasing hormone system (LNG-IUS)--a systematic enquiry and overview. Eur J Obstet Gynecol Reprod Biol 2006; 125:9.</a></li><li><a class="nounderline abstract_t">Bahamondes L, Petta CA, Fernandes A, Monteiro I. Use of the levonorgestrel-releasing intrauterine system in women with endometriosis, chronic pelvic pain and dysmenorrhea. Contraception 2007; 75:S134.</a></li><li><a class="nounderline abstract_t">Lindh I, Milsom I. The influence of intrauterine contraception on the prevalence and severity of dysmenorrhea: a longitudinal population study. Hum Reprod 2013; 28:1953.</a></li><li><a class="nounderline abstract_t">Imai A, Matsunami K, Takagi H, Ichigo S. Levonorgestrel-releasing intrauterine device used for dysmenorrhea: five-year literature review. Clin Exp Obstet Gynecol 2014; 41:495.</a></li><li class="breakAll">Mirena [package insert]. Whippany, NJ: Bayer HealthCare Pharmaceuticals; 2017.</li><li class="breakAll">Liletta [package insert]. Irvine, CA: Allergan USA, Inc; 2017.</li><li><a class="nounderline abstract_t">Lethaby A, Hussain M, Rishworth JR, Rees MC. Progesterone or progestogen-releasing intrauterine systems for heavy menstrual bleeding. Cochrane Database Syst Rev 2015; :CD002126.</a></li><li class="breakAll">Kyleena [package insert]. Whippany, NJ: Bayer HealthCare Pharmaceuticals Inc; 2016.</li><li class="breakAll">Skyla [package insert]. Whippany, NJ: Bayer HealthCare Pharmaceuticals Inc; 2016.</li><li><a class="nounderline abstract_t">Sergison JE, Maldonado LY, Gao X, Hubacher D. Levonorgestrel intrauterine system associated amenorrhea: a systematic review and metaanalysis. Am J Obstet Gynecol 2019; 220:440.</a></li><li><a class="nounderline abstract_t">Petta CA, Ferriani RA, Abrao MS, et al. Randomized clinical trial of a levonorgestrel-releasing intrauterine system and a depot GnRH analogue for the treatment of chronic pelvic pain in women with endometriosis. Hum Reprod 2005; 20:1993.</a></li><li><a class="nounderline abstract_t">Bragheto AM, Caserta N, Bahamondes L, Petta CA. Effectiveness of the levonorgestrel-releasing intrauterine system in the treatment of adenomyosis diagnosed and monitored by magnetic resonance imaging. Contraception 2007; 76:195.</a></li><li><a class="nounderline abstract_t">Croxatto HB. Clinical profile of Implanon: a single-rod etonogestrel contraceptive implant. Eur J Contracept Reprod Health Care 2000; 5 Suppl 2:21.</a></li><li><a class="nounderline abstract_t">Walch K, Unfried G, Huber J, et al. Implanon versus medroxyprogesterone acetate: effects on pain scores in patients with symptomatic endometriosis--a pilot study. Contraception 2009; 79:29.</a></li><li><a class="nounderline abstract_t">Mansour D, Korver T, Marintcheva-Petrova M, Fraser IS. The effects of Implanon on menstrual bleeding patterns. Eur J Contracept Reprod Health Care 2008; 13 Suppl 1:13.</a></li><li><a class="nounderline abstract_t">Casper RF. Progestin-only pills may be a better first-line treatment for endometriosis than combined estrogen-progestin contraceptive pills. Fertil Steril 2017; 107:533.</a></li><li><a class="nounderline abstract_t">Strowitzki T, Faustmann T, Gerlinger C, Seitz C. Dienogest in the treatment of endometriosis-associated pelvic pain: a 12-week, randomized, double-blind, placebo-controlled study. Eur J Obstet Gynecol Reprod Biol 2010; 151:193.</a></li><li><a class="nounderline abstract_t">Strowitzki T, Marr J, Gerlinger C, et al. Dienogest is as effective as leuprolide acetate in treating the painful symptoms of endometriosis: a 24-week, randomized, multicentre, open-label trial. Hum Reprod 2010; 25:633.</a></li><li><a class="nounderline abstract_t">Al-Jefout M, Nawaiseh N. Continuous Norethisterone Acetate versus Cyclical Drospirenone 3 mg/Ethinyl Estradiol 20 μg for the Management of Primary Dysmenorrhea in Young Adult Women. J Pediatr Adolesc Gynecol 2016; 29:143.</a></li><li><a class="nounderline abstract_t">Zigler RE, McNicholas C. Unscheduled vaginal bleeding with progestin-only contraceptive use. Am J Obstet Gynecol 2017; 216:443.</a></li><li><a class="nounderline abstract_t">Bergendal A, Kieler H, Sundström A, et al. Risk of venous thromboembolism associated with local and systemic use of hormone therapy in peri- and postmenopausal women and in relation to type and route of administration. Menopause 2016; 23:593.</a></li><li><a class="nounderline abstract_t">Kuhnz W, Heuner A, Hümpel M, et al. In vivo conversion of norethisterone and norethisterone acetate to ethinyl etradiol in postmenopausal women. Contraception 1997; 56:379.</a></li><li><a class="nounderline abstract_t">Brosnan JF, Sheppard BL, Kelly LA, et al. Norethisterone acetate alters coagulation gene expression in vitro in human cell culture. Thromb Res 2013; 131:72.</a></li><li class="breakAll">Aygestin- norethindrone acetate tablet. US Food and Drug Administration (FDA) approved product information. Revised August, 2019. US National Library of Medicine. www.dailymed.nlm.nih.gov (Accessed on January 22, 2021).</li><li><a class="nounderline abstract_t">Harel Z, Biro FM, Kollar LM. Depo-Provera in adolescents: effects of early second injection or prior oral contraception. J Adolesc Health 1995; 16:379.</a></li><li><a class="nounderline abstract_t">Hubacher D, Lopez L, Steiner MJ, Dorflinger L. Menstrual pattern changes from levonorgestrel subdermal implants and DMPA: systematic review and evidence-based comparisons. Contraception 2009; 80:113.</a></li><li><a class="nounderline abstract_t">Proctor ML, Smith CA, Farquhar CM, Stones RW. Transcutaneous electrical nerve stimulation and acupuncture for primary dysmenorrhoea. Cochrane Database Syst Rev 2002; :CD002123.</a></li><li><a class="nounderline abstract_t">Bai HY, Bai HY, Yang ZQ. Effect of transcutaneous electrical nerve stimulation therapy for the treatment of primary dysmenorrheal. Medicine (Baltimore) 2017; 96:e7959.</a></li><li><a class="nounderline abstract_t">Igwea SE, Tabansi-Ochuogu CS, Abaraogu UO. TENS and heat therapy for pain relief and quality of life improvement in individuals with primary dysmenorrhea: A systematic review. Complement Ther Clin Pract 2016; 24:86.</a></li><li><a class="nounderline abstract_t">Dawood MY. Primary dysmenorrhea: advances in pathogenesis and management. Obstet Gynecol 2006; 108:428.</a></li><li><a class="nounderline abstract_t">Smith RP, Heltzel JA. Interrelation of analgesia and uterine activity in women with primary dysmenorrhea. A preliminary report. J Reprod Med 1991; 36:260.</a></li><li><a class="nounderline abstract_t">Ling FW. Randomized controlled trial of depot leuprolide in patients with chronic pelvic pain and clinically suspected endometriosis. Pelvic Pain Study Group. Obstet Gynecol 1999; 93:51.</a></li><li><a class="nounderline abstract_t">ACOG Committee on Practice Bulletins--Gynecology. ACOG practice bulletin. Medical management of endometriosis. Number 11, December 1999 (replaces Technical Bulletin Number 184, September 1993). Clinical management guidelines for obstetrician-gynecologists. Int J Gynaecol Obstet 2000; 71:183. Reaffirmed 2018.</a></li><li><a class="nounderline abstract_t">Missmer SA, Hankinson SE, Spiegelman D, et al. Incidence of laparoscopically confirmed endometriosis by demographic, anthropometric, and lifestyle factors. Am J Epidemiol 2004; 160:784.</a></li><li><a class="nounderline abstract_t">Chatman DL, Ward AB. Endometriosis in adolescents. J Reprod Med 1982; 27:156.</a></li><li><a class="nounderline abstract_t">Goldstein DP, deCholnoky C, Emans SJ, Leventhal JM. Laparoscopy in the diagnosis and management of pelvic pain in adolescents. J Reprod Med 1980; 24:251.</a></li><li><a class="nounderline abstract_t">Reese KA, Reddy S, Rock JA. Endometriosis in an adolescent population: the Emory experience. J Pediatr Adolesc Gynecol 1996; 9:125.</a></li><li><a class="nounderline abstract_t">Laufer MR, Goitein L, Bush M, et al. Prevalence of endometriosis in adolescent girls with chronic pelvic pain not responding to conventional therapy. J Pediatr Adolesc Gynecol 1997; 10:199.</a></li><li><a class="nounderline abstract_t">Wyatt SN, Banahan T, Tang Y, et al. Effect of Radiofrequency Endometrial Ablation on Dysmenorrhea. J Minim Invasive Gynecol 2016; 23:1163.</a></li><li><a class="nounderline abstract_t">Proctor ML, Murphy PA, Pattison HM, et al. Behavioural interventions for primary and secondary dysmenorrhoea. Cochrane Database Syst Rev 2007; :CD002248.</a></li><li><a class="nounderline abstract_t">Rogers SK, Galloway A, Hirsh AT, et al. Efficacy of psychological interventions for dysmenorrhea: a meta-analysis. Pain Med 2023; 24:1086.</a></li><li><a class="nounderline abstract_t">López-Liria R, Torres-Álamo L, Vega-Ramírez FA, et al. Efficacy of Physiotherapy Treatment in Primary Dysmenorrhea: A Systematic Review and Meta-Analysis. Int J Environ Res Public Health 2021; 18.</a></li><li><a class="nounderline abstract_t">Bandara EMIA, Kularathne WNI, Brain K, Weerasekara I. Safety and efficacy of therapeutic taping in primary dysmenorrhea: a systematic review and meta-analysis. Sci Rep 2022; 12:7146.</a></li><li><a class="nounderline abstract_t">Özgül S, Nalan Çinar G, Gürşen C, et al. The Effects of Connective Tissue Manipulation in Primary Dysmenorrhea: a Randomized Placebo-Controlled Study. Reprod Sci 2023; 30:181.</a></li><li><a class="nounderline abstract_t">Smith CA, Armour M, Zhu X, et al. Acupuncture for dysmenorrhoea. Cochrane Database Syst Rev 2016; 4:CD007854.</a></li><li><a class="nounderline abstract_t">Woo HL, Ji HR, Pak YK, et al. The efficacy and safety of acupuncture in women with primary dysmenorrhea: A systematic review and meta-analysis. Medicine (Baltimore) 2018; 97:e11007.</a></li><li><a class="nounderline abstract_t">Blödt S, Pach D, Eisenhart-Rothe SV, et al. Effectiveness of app-based self-acupressure for women with menstrual pain compared to usual care: a randomized pragmatic trial. Am J Obstet Gynecol 2018; 218:227.e1.</a></li><li><a class="nounderline abstract_t">Gaubeca-Gilarranz A, Fernández-de-Las-Peñas C, Medina-Torres JR, et al. Effectiveness of dry needling of rectus abdominis trigger points for the treatment of primary dysmenorrhoea: a randomised parallel-group trial. Acupunct Med 2018; 36:302.</a></li><li><a class="nounderline abstract_t">Xuan Y, Zhang H, Liu D, et al. The efficacy and safety of simple-needling for the treatment of primary dysmenorrhea compared with ibuprofen: A systematic review and meta-analysis. Medicine (Baltimore) 2022; 101:e28919.</a></li><li><a class="nounderline abstract_t">Proctor ML, Hing W, Johnson TC, Murphy PA. Spinal manipulation for primary and secondary dysmenorrhoea. Cochrane Database Syst Rev 2006; :CD002119.</a></li><li><a class="nounderline abstract_t">Proctor ML, Murphy PA. Herbal and dietary therapies for primary and secondary dysmenorrhoea. Cochrane Database Syst Rev 2001; :CD002124.</a></li><li><a class="nounderline abstract_t">Zhu X, Proctor M, Bensoussan A, et al. Chinese herbal medicine for primary dysmenorrhoea. Cochrane Database Syst Rev 2007; :CD005288.</a></li><li><a class="nounderline abstract_t">Boztaş Elverişli G, Armağan N, Atilgan E. Comparison of the efficacy of pharmacological and nonpharmacological treatments in women with primary dysmenorrhea: randomized controlled parallel-group study. Ginekol Pol 2022.</a></li><li><a class="nounderline abstract_t">Pattanittum P, Kunyanone N, Brown J, et al. Dietary supplements for dysmenorrhoea. Cochrane Database Syst Rev 2016; 3:CD002124.</a></li><li><a class="nounderline abstract_t">Barnard ND, Scialli AR, Hurlock D, Bertron P. Diet and sex-hormone binding globulin, dysmenorrhea, and premenstrual symptoms. Obstet Gynecol 2000; 95:245.</a></li><li><a class="nounderline abstract_t">Abdul-Razzak KK, Ayoub NM, Abu-Taleb AA, Obeidat BA. Influence of dietary intake of dairy products on dysmenorrhea. J Obstet Gynaecol Res 2010; 36:377.</a></li><li><a class="nounderline abstract_t">Ziaei S, Faghihzadeh S, Sohrabvand F, et al. A randomised placebo-controlled trial to determine the effect of vitamin E in treatment of primary dysmenorrhoea. BJOG 2001; 108:1181.</a></li><li><a class="nounderline abstract_t">Ziaei S, Zakeri M, Kazemnejad A. A randomised controlled trial of vitamin E in the treatment of primary dysmenorrhoea. BJOG 2005; 112:466.</a></li><li><a class="nounderline abstract_t">Lasco A, Catalano A, Benvenga S. Improvement of primary dysmenorrhea caused by a single oral dose of vitamin D: results of a randomized, double-blind, placebo-controlled study. Arch Intern Med 2012; 172:366.</a></li><li><a class="nounderline abstract_t">Sanders KM, Stuart AL, Williamson EJ, et al. Annual high-dose oral vitamin D and falls and fractures in older women: a randomized controlled trial. JAMA 2010; 303:1815.</a></li><li><a class="nounderline abstract_t">Daily JW, Zhang X, Kim DS, Park S. Efficacy of Ginger for Alleviating the Symptoms of Primary Dysmenorrhea: A Systematic Review and Meta-analysis of Randomized Clinical Trials. Pain Med 2015; 16:2243.</a></li><li><a class="nounderline abstract_t">Shirvani MA, Motahari-Tabari N, Alipour A. The effect of mefenamic acid and ginger on pain relief in primary dysmenorrhea: a randomized clinical trial. Arch Gynecol Obstet 2015; 291:1277.</a></li><li><a class="nounderline abstract_t">Ozgoli G, Goli M, Moattar F. Comparison of effects of ginger, mefenamic acid, and ibuprofen on pain in women with primary dysmenorrhea. J Altern Complement Med 2009; 15:129.</a></li><li><a class="nounderline abstract_t">Rahnama P, Montazeri A, Huseini HF, et al. Effect of Zingiber officinale R. rhizomes (ginger) on pain relief in primary dysmenorrhea: a placebo randomized trial. BMC Complement Altern Med 2012; 12:92.</a></li><li><a class="nounderline abstract_t">Mohammadi MM, Mirjalili R, Faraji A. The impact of omega-3 polyunsaturated fatty acids on primary dysmenorrhea: a systematic review and meta-analysis of randomized controlled trials. Eur J Clin Pharmacol 2022; 78:721.</a></li><li><a class="nounderline abstract_t">Fedele L, Marchini M, Acaia B, et al. Dynamics and significance of placebo response in primary dysmenorrhea. Pain 1989; 36:43.</a></li><li><a class="nounderline abstract_t">Proctor ML, Latthe PM, Farquhar CM, et al. Surgical interruption of pelvic nerve pathways for primary and secondary dysmenorrhoea. Cochrane Database Syst Rev 2005; :CD001896.</a></li><li><a class="nounderline abstract_t">Latthe PM, Proctor ML, Farquhar CM, et al. Surgical interruption of pelvic nerve pathways in dysmenorrhea: a systematic review of effectiveness. Acta Obstet Gynecol Scand 2007; 86:4.</a></li><li><a class="nounderline abstract_t">Leonardi M, Armour M, Gibbons T, et al. Surgical interventions for the management of chronic pelvic pain in women. Cochrane Database Syst Rev 2021; 12:CD008212.</a></li><li><a class="nounderline abstract_t">Ramirez C, Donnellan N. Pelvic denervation procedures for dysmenorrhea. Curr Opin Obstet Gynecol 2017; 29:225.</a></li><li><a class="nounderline abstract_t">Attar E, Bulun SE. Aromatase inhibitors: the next generation of therapeutics for endometriosis? Fertil Steril 2006; 85:1307.</a></li><li><a class="nounderline abstract_t">Mousa NA, Bedaiwy MA, Casper RF. Aromatase inhibitors in the treatment of severe endometriosis. Obstet Gynecol 2007; 109:1421.</a></li><li><a class="nounderline abstract_t">Moya RA, Moisa CF, Morales F, et al. Transdermal glyceryl trinitrate in the management of primary dysmenorrhea. Int J Gynaecol Obstet 2000; 69:113.</a></li><li><a class="nounderline abstract_t">Facchinetti F, Sgarbi L, Piccinini F, Volpe A. A comparison of glyceryl trinitrate with diclofenac for the treatment of primary dysmenorrhea: an open, randomized, cross-over trial. Gynecol Endocrinol 2002; 16:39.</a></li><li><a class="nounderline abstract_t">Morgan PJ, Kung R, Tarshis J. Nitroglycerin as a uterine relaxant: a systematic review. J Obstet Gynaecol Can 2002; 24:403.</a></li><li><a class="nounderline abstract_t">Andersson KE, Ulmsten U. Effects of nifedipine on myometrial activity and lower abdominal pain in women with primary dysmenorrhoea. Br J Obstet Gynaecol 1978; 85:142.</a></li><li><a class="nounderline abstract_t">Ulmsten U. Calcium blockade as a rapid pharmacological test to evaluate primary dysmenorrhea. Gynecol Obstet Invest 1985; 20:78.</a></li><li><a class="nounderline abstract_t">Sandahl B, Ulmsten U, Andersson KE. Trial of the calcium antagonist nifedipine in the treatment of primary dysmenorrhoea. Arch Gynecol 1979; 227:147.</a></li><li><a class="nounderline abstract_t">Earl RA, Grivell RM. Nifedipine for primary dysmenorrhoea. Cochrane Database Syst Rev 2021; 12:CD012912.</a></li><li><a class="nounderline abstract_t">Dmitrovic R, Kunselman AR, Legro RS. Sildenafil citrate in the treatment of pain in primary dysmenorrhea: a randomized controlled trial. Hum Reprod 2013; 28:2958.</a></li><li><a class="nounderline abstract_t">Pomeroy AR, Rand MJ. Anticholinergic effects and passage through the intestinal wall of N-butylhyoscine bromide. J Pharm Pharmacol 1969; 21:180.</a></li><li><a class="nounderline abstract_t">Kemp JH. "Buscopan" in spasmodic dysmenorrhoea. Curr Med Res Opin 1972; 1:19.</a></li><li><a class="nounderline abstract_t">Oladosu FA, Tu FF, Hellman KM. Nonsteroidal antiinflammatory drug resistance in dysmenorrhea: epidemiology, causes, and treatment. Am J Obstet Gynecol 2018; 218:390.</a></li></ol></div><div id="topicVersionRevision">Topic 5414 Version 58.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31248919" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Productivity loss due to menstruation-related symptoms: a nationwide cross-sectional survey among 32 748 women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29630882" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Physical activity for primary dysmenorrhea: a systematic review and meta-analysis of randomized controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27315239" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Effects of a Yoga Program on Menstrual Cramps and Menstrual Distress in Undergraduate Students with Primary Dysmenorrhea: A Single-Blind, Randomized Controlled Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31071464" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Effectiveness of a treadmill-based aerobic exercise intervention on pain, daily functioning, and quality of life in women with primary dysmenorrhea: A randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31195099" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : The Effect of Zumba Exercise on Reducing Menstrual Pain in Young Women with Primary Dysmenorrhea: A Randomized Controlled Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29529975" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Randomized Trial of Modified Stretching Exercise Program for Menstrual Low Back Pain.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29417063" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : The Effect of aerobic exercise on primary dysmenorrhea: A clinical trial study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29037637" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Effect of yoga on the menstrual pain, physical fitness, and quality of life of young women with primary dysmenorrhea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30696591" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Does aerobic exercise induced-analgesia occur through hormone and inflammatory cytokine-mediated mechanisms in primary dysmenorrhea?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11239634" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Continuous low-level topical heat in the treatment of dysmenorrhea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15493566" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Continuous, low-level, topical heat wrap therapy as compared to acetaminophen for primary dysmenorrhea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22913409" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Comparing the analgesic effect of heat patch containing iron chip and ibuprofen for primary dysmenorrhea: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26340453" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Efficacy of the device combining high-frequency transcutaneous electrical nerve stimulation and thermotherapy for relieving primary dysmenorrhea: a randomized, single-blind, placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26224322" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Nonsteroidal anti-inflammatory drugs for dysmenorrhoea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6419611" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Prostaglandin synthetase inhibitors in the treatment of primary dysmenorrhea. Outcome trials reviewed.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9692420" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Efficacy of minor analgesics in primary dysmenorrhoea: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20159173" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Nonsteroidal anti-inflammatory drugs and hormonal contraceptives for pain relief from dysmenorrhea: a review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/376875" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Use of mefenamic acid in the treatment of primary dysmenorrhea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12380631" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Comparison of the efficacy and safety of nonprescription doses of naproxen and naproxen sodium with ibuprofen, acetaminophen, and placebo in the treatment of primary dysmenorrhea: a pooled analysis of five studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29587566" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Comparison of the efficacy and safety of non-steroidal anti-inflammatory drugs for patients with primary dysmenorrhea: A network meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29587566" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Comparison of the efficacy and safety of non-steroidal anti-inflammatory drugs for patients with primary dysmenorrhea: A network meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11425807" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Induction of delayed follicular rupture in the human by the selective COX-2 inhibitor rofecoxib: a randomized double-blind study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21236424" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Maturation and fertilization of nonhuman primate oocytes are compromised by oral administration of a cyclooxygenase-2 inhibitor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16855077" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Delay of ovulation by meloxicam in healthy cycling volunteers: A placebo-controlled, double-blind, crossover study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19933235" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Suppression of follicular rupture with meloxicam, a cyclooxygenase-2 inhibitor: potential for emergency contraception.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11704117" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : The effect of nonsteroidal anti-inflammatory drugs on ovulation: a prospective, randomized clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Effect of a prostaglandin inhibitor of human ovulation</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6574683" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : The effect of a prostaglandin synthetase inhibitor on the hormonal profile and the endometrium in women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8774286" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Effects of indomethacin on follicular structure, vascularity, and function over the periovulatory period in women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3552753" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Pharmacologic production of luteinized unruptured follicles by prostaglandin synthetase inhibitors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11684206" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Reproductive consequences of COX-2 inhibition.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15037388" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : The potential danger of COX-2 inhibitors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31339951" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Self-care strategies and sources of knowledge on menstruation in 12,526 young women with dysmenorrhea: A systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17407641" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Efficacy of a paracetamol and caffeine combination in the treatment of the key symptoms of primary dysmenorrhoea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15013925" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Is acetaminophen, and its combination with pamabrom, an effective therapeutic option in primary dysmenorrhoea?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19821293" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Oral contraceptive pill for primary dysmenorrhoea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24713413" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Estradiol valerate plus dienogest versus ethinylestradiol plus levonorgestrel for the treatment of primary dysmenorrhea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15994623" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Oral contraceptives for dysmenorrhea in adolescent girls: a randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14561538" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Effect of a low-dose oral contraceptive containing 20 microg ethinylestradiol and 150 microg desogestrel on dysmenorrhea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15157791" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Cycle control, quality of life and acne with two low-dose oral contraceptives containing 20 microg ethinylestradiol.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8605781" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : A twelve-month comparative clinical investigation of two low-dose oral contraceptives containing 20 micrograms ethinylestradiol/75 micrograms gestodene and 20 micrograms ethinylestradiol/150 micrograms desogestrel, with respect to efficacy, cycle control and tolerance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12499030" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Primary dysmenorrhea treatment with a desogestrel-containing low-dose oral contraceptive.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16034942" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Continuous or extended cycle vs. cyclic use of combined oral contraceptives for contraception.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20159177" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Bleeding patterns and menstrual-related symptoms with the continuous use of a contraceptive combination of ethinylestradiol and drospirenone: a randomized study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12066088" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Acceptance of altering the standard 21-day/7-day oral contraceptive regimen to delay menses and reduce hormone withdrawal symptoms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28625286" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : No. 345-Primary Dysmenorrhea Consensus Guideline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17519147" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : The contraceptive vaginal ring compared with the combined oral contraceptive pill: a comprehensive review of randomized controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11343482" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Evaluation of contraceptive efficacy and cycle control of a transdermal contraceptive patch vs an oral contraceptive: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16325993" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Non-contraceptive uses of levonorgestrel-releasing hormone system (LNG-IUS)--a systematic enquiry and overview.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17531605" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Use of the levonorgestrel-releasing intrauterine system in women with endometriosis, chronic pelvic pain and dysmenorrhea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23578948" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : The influence of intrauterine contraception on the prevalence and severity of dysmenorrhea: a longitudinal population study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25864246" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Levonorgestrel-releasing intrauterine device used for dysmenorrhea: five-year literature review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25864246" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Levonorgestrel-releasing intrauterine device used for dysmenorrhea: five-year literature review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25864246" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Levonorgestrel-releasing intrauterine device used for dysmenorrhea: five-year literature review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25924648" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Progesterone or progestogen-releasing intrauterine systems for heavy menstrual bleeding.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25924648" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Progesterone or progestogen-releasing intrauterine systems for heavy menstrual bleeding.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25924648" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Progesterone or progestogen-releasing intrauterine systems for heavy menstrual bleeding.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30527945" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Levonorgestrel intrauterine system associated amenorrhea: a systematic review and metaanalysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15790607" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Randomized clinical trial of a levonorgestrel-releasing intrauterine system and a depot GnRH analogue for the treatment of chronic pelvic pain in women with endometriosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17707716" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Effectiveness of the levonorgestrel-releasing intrauterine system in the treatment of adenomyosis diagnosed and monitored by magnetic resonance imaging.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11246604" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Clinical profile of Implanon: a single-rod etonogestrel contraceptive implant.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19041438" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Implanon versus medroxyprogesterone acetate: effects on pain scores in patients with symptomatic endometriosis--a pilot study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18330814" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : The effects of Implanon on menstrual bleeding patterns.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28162779" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Progestin-only pills may be a better first-line treatment for endometriosis than combined estrogen-progestin contraceptive pills.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20444534" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Dienogest in the treatment of endometriosis-associated pelvic pain: a 12-week, randomized, double-blind, placebo-controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20089522" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Dienogest is as effective as leuprolide acetate in treating the painful symptoms of endometriosis: a 24-week, randomized, multicentre, open-label trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26342733" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Continuous Norethisterone Acetate versus Cyclical Drospirenone 3 mg/Ethinyl Estradiol 20 μg for the Management of Primary Dysmenorrhea in Young Adult Women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27988268" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Unscheduled vaginal bleeding with progestin-only contraceptive use.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27023862" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Risk of venous thromboembolism associated with local and systemic use of hormone therapy in peri- and postmenopausal women and in relation to type and route of administration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9494772" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : In vivo conversion of norethisterone and norethisterone acetate to ethinyl etradiol in postmenopausal women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22999413" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Norethisterone acetate alters coagulation gene expression in vitro in human cell culture.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22999413" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Norethisterone acetate alters coagulation gene expression in vitro in human cell culture.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7662688" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Depo-Provera in adolescents: effects of early second injection or prior oral contraception.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19631785" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Menstrual pattern changes from levonorgestrel subdermal implants and DMPA: systematic review and evidence-based comparisons.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11869624" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Transcutaneous electrical nerve stimulation and acupuncture for primary dysmenorrhoea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28885348" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Effect of transcutaneous electrical nerve stimulation therapy for the treatment of primary dysmenorrheal.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27502806" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : TENS and heat therapy for pain relief and quality of life improvement in individuals with primary dysmenorrhea: A systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16880317" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Primary dysmenorrhea: advances in pathogenesis and management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2072357" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Interrelation of analgesia and uterine activity in women with primary dysmenorrhea. A preliminary report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9916956" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Randomized controlled trial of depot leuprolide in patients with chronic pelvic pain and clinically suspected endometriosis. Pelvic Pain Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11186465" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : ACOG practice bulletin. Medical management of endometriosis. Number 11, December 1999 (replaces Technical Bulletin Number 184, September 1993). Clinical management guidelines for obstetrician-gynecologists.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15466501" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Incidence of laparoscopically confirmed endometriosis by demographic, anthropometric, and lifestyle factors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6211546" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Endometriosis in adolescents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6448296" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Laparoscopy in the diagnosis and management of pelvic pain in adolescents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8795787" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Endometriosis in an adolescent population: the Emory experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9391902" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Prevalence of endometriosis in adolescent girls with chronic pelvic pain not responding to conventional therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27590567" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Effect of Radiofrequency Endometrial Ablation on Dysmenorrhea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17636702" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Behavioural interventions for primary and secondary dysmenorrhoea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37154693" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Efficacy of psychological interventions for dysmenorrhea: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34360122" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Efficacy of Physiotherapy Treatment in Primary Dysmenorrhea: A Systematic Review and Meta-Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35504906" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Safety and efficacy of therapeutic taping in primary dysmenorrhea: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35556238" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : The Effects of Connective Tissue Manipulation in Primary Dysmenorrhea: a Randomized Placebo-Controlled Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27087494" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Acupuncture for dysmenorrhoea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29879061" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : The efficacy and safety of acupuncture in women with primary dysmenorrhea: A systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29155036" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Effectiveness of app-based self-acupressure for women with menstrual pain compared to usual care: a randomized pragmatic trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29720379" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Effectiveness of dry needling of rectus abdominis trigger points for the treatment of primary dysmenorrhoea: a randomised parallel-group trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35363216" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : The efficacy and safety of simple-needling for the treatment of primary dysmenorrhea compared with ibuprofen: A systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16855988" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Spinal manipulation for primary and secondary dysmenorrhoea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11687013" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Herbal and dietary therapies for primary and secondary dysmenorrhoea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17943847" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Chinese herbal medicine for primary dysmenorrhoea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35419791" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Comparison of the efficacy of pharmacological and nonpharmacological treatments in women with primary dysmenorrhea: randomized controlled parallel-group study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27000311" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Dietary supplements for dysmenorrhoea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10674588" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Diet and sex-hormone binding globulin, dysmenorrhea, and premenstrual symptoms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20492391" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Influence of dietary intake of dairy products on dysmenorrhea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11762659" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : A randomised placebo-controlled trial to determine the effect of vitamin E in treatment of primary dysmenorrhoea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15777446" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : A randomised controlled trial of vitamin E in the treatment of primary dysmenorrhoea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22371927" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Improvement of primary dysmenorrhea caused by a single oral dose of vitamin D: results of a randomized, double-blind, placebo-controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20460620" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Annual high-dose oral vitamin D and falls and fractures in older women: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26177393" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Efficacy of Ginger for Alleviating the Symptoms of Primary Dysmenorrhea: A Systematic Review and Meta-analysis of Randomized Clinical Trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25399316" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : The effect of mefenamic acid and ginger on pain relief in primary dysmenorrhea: a randomized clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19216660" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Comparison of effects of ginger, mefenamic acid, and ibuprofen on pain in women with primary dysmenorrhea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22781186" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : Effect of Zingiber officinale R. rhizomes (ginger) on pain relief in primary dysmenorrhea: a placebo randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35059756" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : The impact of omega-3 polyunsaturated fatty acids on primary dysmenorrhea: a systematic review and meta-analysis of randomized controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2919094" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : Dynamics and significance of placebo response in primary dysmenorrhea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16235288" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : Surgical interruption of pelvic nerve pathways for primary and secondary dysmenorrhoea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17230282" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : Surgical interruption of pelvic nerve pathways in dysmenorrhea: a systematic review of effectiveness.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34923620" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : Surgical interventions for the management of chronic pelvic pain in women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28683027" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : Pelvic denervation procedures for dysmenorrhea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16647373" id="rid118" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>119 : Aromatase inhibitors: the next generation of therapeutics for endometriosis?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17540816" id="rid119" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>120 : Aromatase inhibitors in the treatment of severe endometriosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10802078" id="rid120" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>121 : Transdermal glyceryl trinitrate in the management of primary dysmenorrhea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11915580" id="rid121" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>122 : A comparison of glyceryl trinitrate with diclofenac for the treatment of primary dysmenorrhea: an open, randomized, cross-over trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12196860" id="rid122" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>123 : Nitroglycerin as a uterine relaxant: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/626724" id="rid123" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>124 : Effects of nifedipine on myometrial activity and lower abdominal pain in women with primary dysmenorrhoea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4054731" id="rid124" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>125 : Calcium blockade as a rapid pharmacological test to evaluate primary dysmenorrhea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/485222" id="rid125" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>126 : Trial of the calcium antagonist nifedipine in the treatment of primary dysmenorrhoea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34921554" id="rid126" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>127 : Nifedipine for primary dysmenorrhoea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23925396" id="rid127" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>128 : Sildenafil citrate in the treatment of pain in primary dysmenorrhea: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4388214" id="rid128" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>129 : Anticholinergic effects and passage through the intestinal wall of N-butylhyoscine bromide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4589399" id="rid129" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>130 : "Buscopan" in spasmodic dysmenorrhoea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28888592" id="rid130" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>131 : Nonsteroidal antiinflammatory drug resistance in dysmenorrhea: epidemiology, causes, and treatment.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
